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In vitro and in vivo evaluation of novel I-domain conjugates for drug targeting to 
immune cells and suppression of EAE in mice  
 
Prakash Manikwar 
The University of Kansas, 2010 
 
The long-term objective of this project is to utilize the I-domain of leukocyte function 
associated antigen-1 (LFA-1) to target antigenic peptides and drugs to intercellular 
adhesion molecule-1 (ICAM-1) expressed on the surface of immune cells. The objectives 
of the dissertation are: 1) to characterize the binding properties of the I-domain to ICAM-
1 receptors on the surface of lymphocytes (Raji cells), and 2) to evaluate the efficacy of 
PLP-I-domain conjugates in suppressing experimental autoimmune encephalomyelitis 
(EAE) in the mouse model, an animal model for multiple sclerosis. To accomplish these 
objectives, the I-domain protein was labeled with fluorescein isothiocyanate (FITC) at 
several lysine residues to produce the FITC-I-domain. Along with trypsin digestion and 
peptide mapping, we utilized a specific fragmentation of the fluorochrome moiety from 
the modified residues in the electrospray ionization-mass spectrometry (ESI-MS) to 
identify the conjugation sites more quickly (Chapter 2). The FITC-I-domain binds to 
ICAM-1 in a calcium-, time- and energy-dependent manner. It enters the Raji cells via 
receptor-mediated endocytosis. FITC-I-domain binding to ICAM-1 was blocked by anti-
I-domain mAb; in contrast, anti-ICAM-1 mAb to D1 and D2-domain enhance FITC-I-
domain binding to ICAM-1 on the cell surface (Chapter 3).  The I-domain protein was 
 iv
conjugated to an antigenic peptide, PLP139-151, to produce PLP-I-domain-1 and -2 
conjugates. We evaluated the biological activities of the conjugates in female SJL/J mice 
induced with EAE (Chapter 4). The in vivo studies showed that PLP-I-domain-1 has 
excellent efficacy in suppressing EAE, similar to that of the best positive control (i.e., 
Ac-PLP-cIBR1-NH2). Although PLP-I-domain-2 could delay the onset of EAE compared 
to PBS, it was not as potent as PLP-I-domain-1. The chemical structure differences 
between PLP-I-domain-1 and -2 were determined using tryptic digestion followed by 
mass spectroscopic analysis. The number of conjugation sites in PLP-I-domain-1 is 
higher than in PLP-I-domain-2; this suggests that these additional sites in PLP-I-domain-
1 contribute to its biological activity. In conclusion, the I-domain protein binds to and is 
internalized by ICAM-1 receptors on the surface of immune cells. The proper 
conjugation of PLP peptides to I-domain (i.e., PLP-I-domain-1) is necessary for 
suppressing EAE in the animal model.  
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CHAPTER 1 
Antigen-Specific Blocking of Immunological Synapse Formation using 
Bifunctional Peptide Inhibitors (BPI) 
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1.1 Immunological Synapse (IS)  
1.1.1 Mechanism of formation of IS  
One of the major events in triggering adaptive immunity is the activation of T cells. T 
cells are activated by the interaction of the T cell receptor (TCR) with the antigen that has 
been processed and presented by an APC via major histocompatibility gene complex 
(MHC).1 Monks et al. (1998) were the first to report the formation of a three-dimensional 
cell-cell contact between a fixed single T cell and an antigen-presenting cell (APC).2 This 
cell-cell contact is an interaction of surface receptors and intracellular proteins in a well-
organized and spatially distributed manner, leading to the formation of two concentric 
rings termed “supramolecular activation clusters” (SMAC). The inner ring is referred as 
the central TCR-SMAC (c-SMAC or Signal-1). It is composed of protein kinase C (PKC-
) surrounded by an outer or peripheral SMAC (p-SMAC or Signal-2) enriched mainly 
with leukocyte function-associated antigen-1 (LFA-1) and talin. Initial contact between 
the T cell and APC involving TCR and MHC-peptide (MHC-p) and other co-stimulatory 
molecules is called the “immunological synapse” (IS).3 Grakoui et al. identified multiple 
stages of TCR engagement during the formation of stable IS in a dynamic environment. 
Initially, it involves central junction formation by adhesion molecules (i.e., ICAM-
1/LFA-1 or Signal-2) and peripheral TCR-MHC-p complex (Signal-1) in a nascent IS; 
this is followed by actin-based MHC-p transportation (translocation) to the center (Fig. 
1). Finally, stabilization of the cluster takes place.  
 
 
 
3
ICAM-1 MHC-II
LFA-1
Antigen processing 
and presentation by 
MHC-II
MHC-II
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Figure 1. Mechanism of immunological synapse formation during T cell and APC 
interaction. (A) Initial contact between Signal-1 (TCR/MHC-II-peptide complex) 
and Signal-2 (LFA-1/ICAM-1 complex). (B) Translocation of Signal-1 and Signal-2 
to form c-SMAC and p-SMAC of the immunological synapse.
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Since its discovery, many molecules involved in IS have been reported, and several of 
these are ligand/receptor pairs. They include TCR (CD4 or CD8)-MHC-p complex;  
adhesion molecules (i.e., LFA-1/intercellular adhesion molecule-1 (ICAM-1) and/or 
ICAM-2; ICAM-3/LFA-1 or DC-SIGN; CD2/LFA-3); positive and negative co-
stimulatory molecules (CD28/B7-1 (CD80) and B7-2 (CD86); cytotoxic T lymphocyte 
antigen (CTLA-4)/B7-1 and B7-2; inducible co-stimulatory molecules (ICOS)/B7h; 
OX40/OX40L; RANKL/RANK; CD40L/CD40; 4-1BB/4-1BBL; programmed death 
(PD-1)/PD-L1/2; and CD27/CD70) molecules (Fig. 2).4-6 The cytoskeletal protein talin 
and CD2-associated protein as well as intracellular signaling proteins such as PKC-, 
LcK, ZAP, Fyn and MEKK2 have also been identified.6-7 The difference in their 
signaling processes has been attributed to the type of interacting co-stimulatory 
molecules; for example, the interaction could be an activation or inhibition, which affects 
the balance between effector and regulatory functions of a T cell. 
There is a need to further understand the structure and function of the IS because of 
its dynamic nature of formation, which is an active process rather than just an 
accumulation of proteins involved in TCR signaling. Initially, it was thought that the IS is 
required for initiating, stabilizing, and sustaining TCR signaling. However, TCR-
mediated tyrosine kinase signaling in T cells occurs even before the maturation of the IS, 
suggesting that T-cell activation takes place even before sustained signaling.8-9 The 
formation of the IS was suggested to initiate multiple tasks, including organizing the 
secretion of cytokines and cytotoxic agents by CD4+ and CD8+ T cells, respectively, 
during their encounter with an APC.9-14 The IS enhances the interaction of CD28/B7-1/2 
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Figure 2. Signaling molecules involved in the interface of T cell and APC
interaction. The interaction between T cell and APC involves several pairs of 
receptors (Signal-1 and -2) and is associated with the release of cytokines (Signal-3). 
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at the center.9 Lezzi et al.15 demonstrated that the activation and deletion of either naïve 
or effector T cells is dependent on the duration of antigenic stimulation. Prolonged 
antigenic stimulation is required for activation of naïve T cells, but it causes apoptosis in 
effector T cells. Furthermore, TCR clustering enhances binding with MHC-p, and the 
cSMAC is an important site for strong TCR signaling.16,17 The internalization of TCR is 
required for down-regulation of TCR signaling.16 The formation of IS may be required 
for gene activation to induce and secrete effector molecules and for intercellular transfer 
of MHC-p complex along with other receptors such as B7-1 from APC to T cell.6, 18-19  
This event may have biological repercussions, allowing T cells to behave as APC, 
altering the cellular functions and over all controlling the immune response itself.20  
1.1.2 Signal-1 
As described earlier, the formation of IS requires both initial antigen-specific (Signal-
1) and distinct co-stimulatory signals (Signal-2) in the two-signal model (Fig. 2).21-22 
Earlier studies demonstrated that a complex formed by an immunogenic peptide and 
purified MHC-II (Ia) molecule was recognized by the TCR.23-24 These findings were 
further confirmed by solving various crystal structures of peptide-MHC complexes.25-33 
Later, the specific TCR recognition of MHC-p complex on the surface of APC as a result 
of antigen processing was termed Signal-1.21-22 
TCR is a disulfide-linked heterodimer belonging to the Ig supergene family in the 
CD3 superfamily, and it consists of /  or / chains. Each chain is composed of two 
extracellular (one variable and one constant), a transmembrane, and a short cytoplasmic 
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domain.34 The variable domain has the greatest diversity in the complementarity-
determining region 3 (CDR3).35 The sequence of CDR3 is primarily involved in 
recognizing the antigenic peptide presented by MHC molecules on APC.36 MHC class I 
and class II molecules on APC bind antigenic peptides derived from endogenous and 
exogenous proteins, respectively. Lipid antigens captured from exogenous antigens bind 
to CD1 MHC-like molecules.37-38 Antigen processing and presentation by MHC class I39-
48 and CD1 MHC-like molecules37, 49-50 have been described elsewhere; thus, they will 
not be described here. 
T lymphocytes are derived from precursors in hematopoietic tissue and undergo cell 
differentiation in thymus. T cells expressing co-receptor molecule CD4 that recognize 
MHC class II-peptide complexes are called CD4+ T cells (or helper T cells) and those 
expressing CD8 that recognize MHC class I-peptide complexes are called CD8+ T cells 
(or cytotoxic T cells).51-54 Upon activation, T cells can differentiate into different helper T 
cells, including TH1 cells (IFN- and lymphotoxin producer),3, 55 TH2 cells (IL-4, IL-13, 
IL-5, and IL-6 cytokine producer),3, 12, 55 or TH17 cells (IL-17 producer).56  Naïve CD4+ T 
cells can also be differentiated into an independent lineage called regulatory T cells (Treg) 
expressing fork-head transcription factor Foxp3 and CD25.56 CD4+ T cells execute many 
important effector functions, depending on the cytokines they secrete.55  CD8+ T cells are 
capable of differentiating into cytotoxic T lymphocytes (CTL);10 these cells recognize 
specific antigens presented by MHC class-I on their target cells and perform cell 
lyses.11,13 
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The MHC class II (MHC-II) molecules are expressed by professional APC (pAPC), 
including dendritic cells (DC), macrophages, and B cells. Each of these pAPC has 
different ways of capturing and processing antigens; for example, DC activate naïve T 
cells more efficiently than do B cells or macrophages.57 Before the presentation of the 
peptide fragments of the antigen, the antigen is first internalized via phagocytosis, fluid-
phase uptake by macropinocytosis, or receptor-mediated endocytosis via mannose and 
lectin-like receptors.58-60 Then, they are processed via early endosome and then 
transferred to late endosome before entering lysosomes.61-65 Because MHC-II 
compartments (MIIC) are rich in lysosomal enzymes, proteins are degraded by lysosomal 
proteases to generate peptide fragments; these peptides are loaded onto MHC-II 
molecules in the MIIC.66-68 The new MHC-II molecules are synthesized and assembled 
with invariant chain (Ii) in the endoplasmic reticulum to form MHC-II-Ii complexes, 
which are then transported to the Golgi apparatus and targeted to the 
endosomal/lysosomal compartments.69-72 The portion of Ii in MHC-II-Ii complex is then 
clipped off by proteases to produce MHC-II molecules with classII-associated invariant 
chain (CLIP). Then, the CLIP is exchanged for antigenic peptide to form the MHC-II-
peptide (MHC-II-p) complex that is transported to the surface of the APC for 
presentation to a CD4+ T cell.48, 68 
The highly polymorphic MHC-II molecules consist of - and -chains, which belong 
to the immunoglobulin supergene family.29 Each chain consists of two extracellular 
domains (1 and 2; 1 and 2, respectively), a transmembrane domain, and a 
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cytoplasmic domain. The antigenic peptide binds to 1- and 1-domains.73  Except for 
the 1 domain of MHC-II, all other extracellular domains possess an intradomain 
disulfide bond. The transmembrane and cytoplasimc domains of MHC-II posses specific 
sequences required for efficient T cell surface expression,74 signaling,75 antigen 
presentation,76-77 and lateral diffusion of MHC-II molecules on the surface of the APC.78 
1.1.3 Signal-2 
 
Signal-2 or the co-stimulatory signal is necessary for amplifying and controlling the 
TCR signaling process, stabilizing the physical association, and regulating the T cell 
response.79-80 The predominant co-stimulatory signal for T-cell activation is delivered by 
interaction between the B7 family of molecules on the APC and CD28 or CTLA-4 
receptors on T cells (Fig. 2).81-83 B7 co-stimulation along with TCR signaling generates 
the upregulation of  α-, β-, and γ-chains of IL-12 receptor,84-87 cytokine transcription,88-89 
T cell proliferation,90-92 and expression of Bcl-χL.93 During T cell-APC interaction, the 
absence of a co-stimulatory signal and the presence of TCR signal produce antigen-
specific unresponsiveness (anergy) of T cells, which can be reversed with IL-12.92, 94 
Blocking the co-stimulatory signal (Signal-2) is the basis for designing therapeutic agents 
for inflammatory and autoimmune diseases. The balance between positive and negative 
signals delivered by CD28 and CTLA-4, respectively, is crucial for regulation of T cell 
proliferation, differentiation, and survival and T cell-dependent B cell responses. CD28 
provides signals that augment and sustain T-cell activation in concert with TCR 
signaling. CTLA-4 (a negative regulator) antagonizes TCR signals to dampen secondary 
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immune responses for inducing tolerance. CD28 is expressed constitutively on all human 
CD4+ T cells and on approximately 50% of human CD8+ T cells.95-96 Its level, however, 
increases after T-cell activation. In contrast to CD28, CTLA-4 is not expressed on resting 
T cells but is present on activated T cells as a late priming molecule and it is observed 
after 24–48 hours with only 2–3% of the levels of CD28 expression.97 The expression of 
CTLA-4 in the immunological synapse is proportional to the strength of the TCR 
stimulus,98 and it recruits Src homology 2 (SH2) domain-containing phosphatase-2 (SHP-
2) upon T-cell activation99 as a negative regulator of T cell responses. 
B7-1 (CD80) and B7-2 (CD86) are the two members of the B7 family primarily 
expressed on APC.90-91, 100 B7-1 is upregulated in response to maturational stimuli, while 
B7-2 is constitutively expressed at low levels and induced rapidly upon activation.101 
CD28 has lower avidity for B7-1 and B7-2 molecules than does CTLA-4.102-103 Both 
types of B7 molecules exist as monomers with conserved residues at the extracellular V-
like and C-type domains that are critical for binding to CD28 and CTLA-4 via the 
MYPPPY motif. B7-1 has a short cytoplasmic tail while B7-2 has a longer cytoplasmic 
tail with three potential phosphorylation sites by PKC. 
Two other co-stimulatory signaling pathways are delivered using inducible 
costimulator (ICOS) and programmed death-1 (PD-1) molecules. ICOS molecule is a 
homodimer linked with a disulfide bond; it is a homolog of CD28 with a FDPPPF motif 
in the V-like domain instead of the MYPPPY motif. ICOS binds to B7h molecule, and its 
stimulation in response to TCR activation increases T cell proliferation104-107 and 
promotes IL-10 production as well as increases IL-4, IL-5, IFN-γ, TNF-α, and GM-CSF 
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production.105 In addition it plays an important role in tolerance induction.108-109  Due to 
the absence of the MYPPPY binding motif, ICOS does not bind to B7-1 and B7-2.107, 110  
B7h is expressed constitutively by B cells and macrophages, and its expression can be 
induced by inflammatory stimuli on non-lymphoid cells, including endothelial cells, 
fibroblasts, and epithelial cells.  
The PD-1 molecule has roles in induction and/or maintenance of peripheral tolerance 
and acts as a negative regulator of T cell responses. Functional studies showed that PD-1-
deficient Balb/c mice developed a fatal dilated cardiomyopathy with early disease 
onset,111 The ligands for PD-1 are PD-L1 (Fig. 2) and PD-L2. PD-L1 is widely expressed 
on T cells, B cells, macrophages, monocytes, DCs, and non-lymphoid cells, including 
endothelial cells, syncytiotrophoblasts in the placenta, muscles, and pancreatic islets,113 
while PD-L2 is only found on macrophages and DCs inducible by cytokines.114 PD-1 is 
expressed during thymic development primarily on CD4-CD28- and γ-δ- thymocytes and 
induced on peripheral CD4+ and CD8+ T cells, B cells, and monocytes upon TCR 
stimulation.113 Unlike CTLA-4, PD-1 inhibits expression of the cell survival gene bcl-
XL,113 and both CTLA-4 and PD-1 are known to limit glucose metabolism and Akt 
activation via different pathways. CTLA-4 inhibits Akt activation via protein phosphatase 
2a, and PD-1 inhibits via CD28-mediated activation of PI3K. 
LFA-1 and ICAM-1 are accessory molecules, which have adhesion and/or co-
stimulatory functions (Fig. 2). LFA-1 is a well-established cell-cell adhesion molecule; it 
plays a key role in several of T-cell activation and effector function.115 Functionally, 
LFA-1 has been shown to enhance IL-2 expression, leading to the induction of T cell 
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proliferation. LFA-1 is exclusively expressed on leukocytes and interacts with its ligands 
such as ICAM-1, -2, and -3 to promote a variety of homotypic and heterotypic cell-cell 
adhesion necessary for normal and pathologic functions of the immune systems.  The 
interaction of LFA-1 with its ligands permits allows for improved adhesion of leukocytes 
to vascular endothelium, an essential step in the recruitment and migration of leukocytes 
into inflamed tissue.116-118 Similarly, LFA-1-mediated adhesion is thought to facilitate 
antigen presentation to T cells, and numerous reports indicate that LFA-1 engagement 
decreases the minimal stimulatory dose of antigen by 10- to 100-fold.119-121  
1.1.4 Signal-3  
After Signal-1 and -2 have been initiated, inflammatory cytokines are released in 
order to fully activate the T cell; this is known as Signal-3.122 The inflammatory 
cytokines can be released by the APC (paracrine) or by the T cell itself (autocrine)123 and 
the cytokines are required for the proper proliferation, differentiation, and activation of T 
cells. This signal is also called the “polarizing” signal because after its delivery, helper T 
cells become polarized into either type 1 helper T cells (TH1) or type 2 helper T cells 
(TH2).124 Matzinger proposed the “danger theory,” which states that, for full activation, 
the T cell must receive a “danger” signal provided by cytokines and co-stimulatory 
signals.125-126 Matzinger believed that the immune system was driven by its power to 
recognize danger and deploy an immunizing response that will remove the threat and 
prevent harm to the body.125 If the “danger” signal is not delivered, the immune system 
will induce a tolerizing effect rather than an immunizing effect. 
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To study how the “danger” signal affected the proliferation of CD8+ and CD4+ T 
cells, Mescher et al. employed artificial APC, using microspheres coated with 
immobilized MHC protein/peptide complexes to provide Signal-1 and co-immobilized 
B7-1 protein for Signal-2.122 For CD8+ T cells, they proved that IL-12 was needed along 
with Signal-1 and Signal-2 to stimulate naive CD8+ T cells for optimal proliferation.  
Also, they showed that without IL-12, the T cells do not differentiate into cytolytic 
effector cells and thus they are not fully activated.  In contrast, IL-1 but not IL-12 was 
required for the optimal proliferation of naïve CD4+ T cells. Thus, inflammatory 
cytokines produced by APC are the necessary Signal-3 to optimize the proliferation of 
CD4+ and CD8+ T cells to prevent tolerance toward a specific antigen.  
As a “polarizing” signal, Signal-3 is delivered to naïve helper T cells for their 
differentiation to either TH1 or TH2, and the differentiation depends on the type of 
cytokine delivered as the Signal-3.  If the naïve helper T cells receive IL-12 signal, they 
differentiate into TH1. If they receive IL-4, the helper T cells differentiate into TH2.124 
Once the helper T cells are differentiated, TH1 cells secrete cytokines such as interferon-γ 
(IFN-γ) and tumor necrosis factor-α (TNF-α), which are used to direct T cell immunity 
against intracellular bacteria and viruses.  If the naïve T cell differentiates into TH2 cells, 
their job is to control humoral immunity and immunity against extracellular parasites by 
producing cytokines such as IL-4, IL-5 and IL-13.   
T cells can produce Signal-3 for optimization of their own proliferation.  After the 
delivery of Signal-1 and Signal-2, transductions of several intracellular signals such as 
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the calcium-calcineurin pathway, the RAS-mitogen-activated protein (MAP) kinase 
pathway, and the nuclear factory-κB pathway (NF-κB) are generated.123, 127 These 
pathways activate expression of the most prominent cytokine, IL-2, along with several 
other cytokines (Fig. 2).  Binding of IL-2 to IL-2 receptor (IL-2R) on the surface of the T 
cells followed by other cytokines initiates T cell proliferation via the rapamycin 
pathway.123 Although cytokines are very important for inducing the appropriate T cell 
response, it is still unclear where and how most of these inflammatory cytokines act to set 
off T cell responses in both CD4+ and CD8+ T cells.122 
 
1.2 Antigenic Peptides 
Autoimmune diseases could involve a single organ (e.g., multiple sclerosis, 
rheumatoid arthritis, and diabetes) or no involvement of specific organs (e.g., systemic 
lupus erythematosus).  T cells and B cells are engaged in inflammatory immune 
responses, leading to the onset and progression of autoimmune diseases. Activation of 
both T and B cells depends on antigen presentation. Although antigens are necessary for 
activation of these lymphocytes, several studies have shown that injections of antigenic 
peptides/proteins could also suppress autoimmune diseases. The mechanisms of 
suppression by antigens are thought to work by immune deviation and induction of Treg 
cells. In the following sections, etiologies and current treatments of various autoimmune 
diseases are discussed. 
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1.2.1 Multiple Sclerosis 
Multiple sclerosis (MS) is a complex genetic inflammatory disease in which the 
autoreactive immune cells (i.e., T cells) attack the myelin sheath of the central nervous 
system causing axonal damage, demyelination (Fig. 3), and chronic inflammation (Fig. 
3).128 As a result of myelin sheath damage, the communication between nerve cells is 
disrupted due to interruption of the conduction of the electric impulses along the axons.  
In MS patients, the damage in the myelin sheath affects optic nerves, brainstem, spinal 
cord, cerebellum, and periventricular white matter.  The formation of lesions or plaques 
called sclerosis in the white matter of the brain and the spinal cord are the pathological 
hallmark of the disease. Besides the destruction of the myelin sheath, the lesions are also 
due to the loss of axons and the death of oligodendrocyte cells, which are responsible for 
the formation and maintenance of the myelin sheath. As a result, MS patients suffer from 
muscle weakness, changes in sensation and speech, vision problems, muscle spasms, and 
fatigue.  
Nearly 80% of MS patients have clinical relapses referred to as relapsing-remitting 
MS (RRMS), which is characterized by inflammation of the brain and spinal cord along 
with white matter lesions.129  During the RRMS period, patients have unpredictable 
relapses followed by long remission with no signs and symptoms of the disease; about 
65% of these patients will gradually progress toward a secondary progressive MS 
(SPMS) typified by an irreversible neurological defect.129 About 20% of the patients 
without remission have steady neurological decline from the onset of the disease and are 
categorized as having primary progressive MS (PPMS), which is the least common type. 
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Figure 3. Cartoon representation of a healthy neuron and a demyelinated neuron.
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Both PPMS and SPMS show signs of axonal degeneration, which could be due to loss of 
the myelin sheath. 
The cause of MS has not been fully elucidated; however, it is clear that MS patients 
have a leaky blood-brain barrier (BBB) with brain infiltrations of CD4+/CD8+ T cells, B 
cells, and monocytes.128, 130-131 Although the antigenic target of the immune cells is not 
certain, there is increasing evidence that the T cells recognize self myelin antigens such 
as proteolipid protein (PLP), myelin basic protein (MBP), myelin oligodendrocyte 
glycoprotein (MOG), or antigenic peptides from the immunodominant epitopes of MBP 
(MBP84-104), MOG (MOG35-55 and MOG92-106), or PLP (PLP139-151 and PLP178-191) (Table 
1). Once activated with myelin antigens, naïve CD4+ T cells migrate into the CNS where 
these cells recognize the antigen presented by the local APC called microglia. Naïve 
CD4+ T cells then undergo a process of differentiation into TH1 effector cells, which 
produce proinflammatory cytokines such as IL-2, IFN-, and TNF-.132 In addition to 
TH1 subset activation, a subpopulation of memory CD4+ T cells (TH17) are also activated; 
these cells have been found to secret the proinflammatory cytokine IL-17 under the 
control of IL-6, IL-23, and TGF-.133-134 An elevated level of IL-17 in the blood and CSF 
has been observed in MS patients.135-136 Circulating IL-17 and -22 are responsible for 
disruption of the BBB, which eventually allows TH17 cells to pass through the BBB to 
damage the neuronal cells.129 The experimental autoimmune encephalomyelitis (EAE) 
mouse has been used as a model for MS. Injections of anti-IL-17 monoclonal antibody 
(mAb) after EAE induction in mice prevents the development of the disease, suggesting 
that IL-17 has an important role in the pathogenesis of EAE and MS.134, 137 
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Table 1. List of candidate autoantigens in MS, T1D, and RA 
Disease Antigen References 
Multiple 
Sclerosis 
Proteolipid protein (PLP) 
Myelin basic protein (MBP) 
Myelin oligodendrocyte glycoprotein (MOG) 
Astrocyte-protein S100 
314 
Type 1 
Diabetes 
Glutamic acid decarboxylase (GAD) 
Insulin zinc transporter (ZNT8) 
Insulinoma antigen (IA-2) 
Insulin 
161-163 
Rheumatoid 
Arthritis 
Human cartilage gp-39 
Cartilage proteins melanoma inhibitory activity 
(MIA) 
Type II collagen 
Citrullinated proteins (e.g., fibrin) 
315-321  
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Several studies have shown that T cell-mediated immune response to myelin antigens 
can be tolerated by administrating autoantigens. Oral administration of MBP to Lewis 
rats prior to the induction of EAE with MBP and complete Freund’s adjuvant has shown 
to suppress EAE as a result of clonal anergy or deletion of activated T cells.138-141 This 
observation was further supported by a reduction in the number of TH1 MBP-specific 
cells in tolerance-induced rats.141  A one-year, double-blind, clinical study of a small 
group of MS patients administered bovine myelin antigens showed a significant decrease 
in the number of T cells reactive toward myelin basic protein compared to the control 
group.142 In this study, a significant decrease was observed in the number of patients 
undergoing major attacks (6/15) compared to the control group (12/15).142  However, a 
subsequent large, phase III clinical trial failed to confirm the efficacy of a single oral dose 
of myelin antigens (MBP and PLP) due to a large placebo effect. This study has left 
many unanswered questions about the dose or formulation of myelin that might have 
been more effective.  
Alternatively, intrathecal, intravenous (i.v.), subcutaneous (s.c.), or nasal 
administration of antigenic peptides has been investigated to induce tolerance in patients. 
Two phase I trials conducted by Warren and colleagues demonstrated that administration 
of MBP peptides, MBP75-95 or MBP85-96, in chronic progressive multiple sclerosis patients 
did not produce any adverse effects.143-144  Induction of tolerance was monitored by 
detecting the reduction of anti-MBP antibodies in cerebrospinal fluid (CSF). Intrathecal 
administration resulted in transient neutralization whereas intravenous administration 
resulted in long-lasting tolerance or reduction in anti-MBP antibodies for up to one year 
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after a second i.v. dose of antigen. However, s.c. administration of the antigenic peptides 
did not affect the reduction of anti-MBP antibodies in CSF, clearly demonstrating that 
s.c. injection failed to induce tolerance in these patients.144  Unfortunately, these studies 
failed to relate the clinical significance of the reduction in antibodies against MBP and its 
effect on the prognosis of the disease in MS patients.  
Antigenic peptides derived from myelin basic protein were successfully delivered via 
the nasal route and were effective in inhibiting EAE disease in a murine model.145-148 The 
mechanism of tolerance in this model is due to MBP-reactive specific Treg cells that 
produce IL-10. In addition, these cells were found to express higher levels of IL-4 and 
TGF- mRNA.147, 149 Similarly, altered peptide ligands (APL) are mutated antigenic 
peptides with increased affinity for MHC-II and/or TCR, and they have been shown to 
control rheumatoid arthritis and EAE in animal models. A suggested mechanism of 
action for APL in inhibiting antigen-specific T-cell activation is increasing the expression 
of indoleamine 2, 3-dioxygenase (IDO) enzyme in activated T cells. Presumably, the 
increased amount of IDO converts tryptophan to its metabolites (i.e., 3-hydroxykynurenic 
acid (3-HKA), picolinic acid (PA), and quinolinic acid (QA)) and these metabolites 
suppress the EAE relapse by reducing the production of inflammatory cytokines and 
stimulating the production of IL-4 and IL-10 that are related to TH2 and Treg cellular 
differentiation.150 
Current strategies that are approved for the treatment of MS include two classes of 
drugs, these are anti-inflammatory and disease-modifying therapies (DMT). Acute MS 
relapses are often treated with high-doses of intravenous corticosteroids such as 
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methylprednisolone. This is effective for short-term treatment, but it does not have any 
effect on long-term recovery. Mitoxantrone (Novantrone), interferon beta-1a (IFN-1a 
or Avonex/Rebif/CinnoVex), IFN-1b (marketed as Betaseron/Betaferon), 
glatiramer acetate (GA, Copaxone), and natalizumab (Tysabri) are current DMT drugs. 
Mitoxantrone will not cure the disease, but it is effective in slowing the progression of 
SPMS and delaying the relapse interval time in RRMS.151 The mechanism of action of 
mitoxantrone involves disrupting both DNA synthesis and DNA repair. The side effects 
of mitoxantrone are irreversible cardiomyopathy, acute leukemia, and bone marrow 
suppression; patients receiving this treatment are advised to have regular 
echocardiograms.   
IFN-1b was first introduced in 1993 for RRMS treatment. In the clinical trials, 
patients treated with IFN-1b were free from relapse at the end of two years compared to 
a placebo-treated group.152 IFN-1b acts as an anti-inflammatory agent by reducing the 
production of IFN- and TNF- and inhibits T-cell activation, clonal expansion, and 
migration into the CNS.153 The mechanism of action of IFN-1a is thought to be similar 
to that of IFN-1b.  
Copaxone® (glatiramer acetate) is a synthetic peptide polymer (40–100 residues) that 
consists of Glu, Lys, Ala, and Tyr amino acids in a ratio of 3:7:9:2; it is designed as a 
decoy for myelin basic protein (MBP). Copaxone® has been suggested to alter the 
immune response from TH1- to TH2-cell differentiation. 
Finally, natalizumab (Tysabri) is the first recombinant human monoclonal antibody 
(mAb) approved for the treatment of MS. It inhibits leukocyte adhesion to vascular 
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endothelium by binding to the 4-subunit of 41 and 47 integrins on the surface of 
leukocytes to prevent leukocyte infiltration into the CNS.154 Natalizumab has been shown 
to significantly slow the progress of disability with increasing numbers of disease-free 
individuals compared to placebo group. It can also reduce disease relapse, loss of vision, 
and number of lesions in patients.155-157 In spite of its greater efficacy compared to any 
other approved MS therapies, its use is limited because of the development of potential 
fatal adverse effects such as progressive multifocal leukoencephalopathy (PML), 
melanoma, hepatotoxicity, opportunistic infections, and primary CNS lymphoma.158-159 
Recent studies suggest that patients receiving this drug for more than one year are at 
increased risk for PML.160 Currently, the FDA has limited the usage of natalizumab to 
patients not responding to other therapies, and the drug is under a mandatory safety 
monitoring program.  
 
1.2.2 Type-1 Diabetes  
Type 1 diabetes (T1D) is marked by insulitis and the destruction of the pancreatic 
islet of Langerhans beta cells.161 Although not all-inclusive, studies carried out in non-
obese diabetic (NOD) mice show that CD4+ and CD8+ T cells are partly responsible for 
the destruction of the β-cells.5 Those afflicted with T1D are genetically predisposed, and 
the progress toward the disease is initiated after encountering an environmental insult, 
such as diet or microbial infections.5 Insulin, glutamic acid decarboxylase (GAD), zinc 
transporter (ZNT8), and insulinoma antigen (IA-2) are the four major antigens (Table 1) 
for activation of immune cells, and they have been used in assays to detect the progress 
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of T1D.162-163 Glutamic acid carboxylase 65 kDa (GAD65) is considered a target for 
therapy because of its partial role in the activation of certain T cells that recognize it as an 
antigen.161 
The immunotherapy of T1D focuses on two alternative methods of treatment: 
prevention of T1D or treating it at its onset. Ever since its discovery, insulin has been 
considered to be the gold standard of treatment for Type 1 diabetics. Like GAD65,161 
insulin has also received attention as a therapeutic method to suppress the activation of T 
cells.163 By suppressing the activation of T cells, beta-cells may be regenerated, and this 
may lead to the remission of diabetes.5 The administration of autoantigens (GAD65 or 
insulin) and their peptides has been shown to suppress beta-cell autoimmunity.5, 161 
The role of insulin as an autoantigen is still ambiguous.  To date, many epitopes of 
insulin and proinsulin have been identified.163 Recent findings have shown that insulin 
autoantibodies can be induced by insulin B9-23 peptide. NOD mice (H-2d) were 
immunized with B9-23 peptides, which led to the development of MHC-activated 
autoantibodies towards insulin.164 However, it has been shown that the antibodies toward 
insulin react only with insulin and not with NOD B9-23 peptides, suggesting that insulin 
antibodies recognize the whole molecule rather than the peptide sequence itself.163 
Proinsulin, the precursor of insulin, also has a sequence of amino acids (B24-C36) that 
are recognized by NOD mice CD4+ T cells.165 B9-23 has been hypothesized to play an 
important role in humans as it did in NOD mice because the amino acid sequences are 
similar in both species. Higashide and colleagues have shown that the most frequent 
epitopes recognized by T cells are B10-24, B1-15, and B11-25, with B9-23, B4-18, and 
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B12-26 being identified in some patients.166 Alternatively, it has been observed in NOD 
that intranasal vaccines containing proinsulin in a plasmid DNA increased the number of 
Treg cells and effectively prevented the onset of diabetes.167 
GAD65 is an enzyme that is targeted as an autoantigen by T cells. Anti-GAD65 
antibodies can be observed in NOD mice prior to the onset of T1D.  Injection of GAD65, 
intravenously or intrathymically, to young NOD female mice prior to any signs of disease 
has been shown to prevent diabetes and induce CD4+ Treg cells.168 Controlling the 
activation and increasing the induction of Treg cells by GAD65 antigen may help suppress 
T1D.161  Tisch and colleagues revealed that peptides derived from GAD65 are able to 
suppress the progression of T1D in NOD mice prior to the onset of insulitis. The peptides 
used include amino acids: 217-236, 247-265, 290-309, and 524-543.169   
 
1.2.3 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic idiopathic disease characterized by persistent 
inflammation and local destruction in the synovial tissues including the synovium, bone, 
and cartilage. Although the nature of the antigens responsible for RA pathogenesis has 
not been clearly elucidated, there is evidence that the disease-associated HLA DR 
(B1*0401, 0404, 0405, and 0101) molecules, which reside in the MHC and participate in 
antigen presentation, are associated with the disease.170 Viral proteins such as 
cytomegalovirus (CMV) and Epstein-Barr virus (EBV) as well as several autologous 
proteins normally expressed in the joints, including gp39, proteoglycan, and type II 
collagen, have been implicated in the generation of the pathogenic T cell response in RA 
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(Table 1). The driving force behind rheumatoid inflammation is believed to be CD4+ T 
cells responding to an antigenic epitope in the synovium in an HLA-DR-restricted 
manner. Increased numbers of “memory” CD4+ and decreased numbers of “naïve” CD4+ 
T cells in the synovial tissues of RA patients171-172 suggest that CD4+ T cells play a 
crucial role in the pathogenesis of RA. Synovial tissue T cells are enriched with CD4+ T 
cells that do not express the Leu 8 antigen, now known to be the human equivalent of the 
murine homing receptor.173-175 Loss of this molecule is characteristic of activated T cells. 
Synovial fluid also contains augmented expression of the activated antigens HLA-DR, 
CD9, CD38, CD49a/CD29 (VLA-1), and adhesion molecule CD54 (ICAM-1).176-179  
In addition to CD4+ T cells, a number of other inflammatory mediators produced in 
the rheumatoid synovium, including arachidonic acid metabolites, vasoactive amines, 
platelet-activating factor, and complement cleavage products contribute to the 
inflammation. Recently IL-17 produced primarily by the TH17 cells has also been 
implicated in human autoimmune inflammation. A potential key role in diseases such as 
RA has only recently been attributed to IL-17, although it was discovered decades ago. 
Elevated levels of IL-17 in blood and synovium of RA patients have been correlated with 
synovial levels and joint damage.180-182 Recent advancement in research toward new and 
better-tolerated therapies to attenuate the inflammation and pain associated with 
rheumatoid arthritis as well as halt the progression of erosive joint damage has led to the 
development of strategies for modulating stimulation of immune cells or blocking 
cytokines as potential therapeutic strategies.  
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Injections of soluble antigens have been shown to induce antigen-specific immune 
tolerance. It is thought that tolerance could be achieved through anergy/deletion of CD4+ 
T cells or the induction of CD4+ Treg cells that produce IL-10 or TGF-β.183 Oral and, 
more recently nasal, tolerance resulting from administration of antigens has attracted 
attention as a potential treatment of autoimmune diseases. Oral administration of type II 
collagen (CII) has been shown to suppress arthritis in mice184 and rats.185 Oral 
administration of chicken CII to patients with RA provided significantly less progression 
of the disease compared to placebo-treated patients.186  
In another study, peripheral blood mononuclear cells (PBMC) of RA patients 
responded well in vitro to CII256-271 epitope and its overlapping variants.187 Similarly, oral 
administration of this peptide has been shown to suppress arthritis in a CIA mouse 
model.187 Specific T cell activity, proliferation, and secretion of IFN- in spleen cells 
were actively suppressed in CII250–270-fed mice, and the serum anti-CII, anti-CII250–270 
antibody activities and frequency of specific antibody-forming spleen cells were 
significantly lower in CII250–270-fed mice than in controls. Moreover, IL-4-producing cells 
(TH2 cells) were upregulated when CIA mice were treated with type II collagen (CII250-
270), suggesting that oral administration of CII250–270 can suppress the cellular and 
humoral immune response in collagen-induced arthritis. Although the majority of animal 
studies have yielded positive results with the oral tolerance regimen, under some 
circumstances, mucosal application of antigen may instead exacerbate the disease 
process.188  
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Abatacept, also known as CTLA4-Ig, was approved in 2005 by the FDA for the 
treatment of patients with moderate-to-severe active RA who have had an inadequate 
response to disease-modifying antirheumatic drugs (DMARDS), including methotrexate 
(MTX) and TNF antagonists. It is a fusion protein composed of the extracellular domain 
of the CTLA4 molecule complexed to the Fc domain of human IgG1. The IgG1 
solubilizes the fusion protein; thus, unlike the membrane-bound CTLA4 molecule, its 
binding to CD80/CD86 does not induce a negative signal to T cells. Its binding blocks the 
engagement of the CD28 co-stimulatory signal required for T-cell activation, resulting in 
T cell anergy.189 Patients receiving abatacept responded better than those receiving 
placebo. Quality of life was also improved with abatacept and benefits were sustained at 
12 months, these included significant reduction in disease activity as well as improved 
physical function.190 
Infliximab is a chimeric monoclonal antibody that binds to circulating and 
transmembrane TNF-α and thereby neutralizes its biological effect. Circulating TNF-α is 
a form of TNF-α generated by cleavage from the transmembrane precursor. Both forms 
of TNF-α have been shown to sustain the inflammation process. Transgenic mice 
overexpressing TNF-α were observed to develop a destructive arthritis resembling 
rheumatoid arthritis (RA). Moreover, high levels of TNF-α detected in synovial fluid and 
in the tissues of patients with RA191 suggest that TNF-α plays a pivotal role in 
physiologic and pathogenic response.192 In addition to infliximab, a number of agents that 
block TNF-α have been developed for clinical use, including etanercept, adalimumab, 
and certolizumab. Etanercept is a fusion protein consisting of the soluble human TNF-α 
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receptor linked to the Fc-portion of the human IgG1. Adalimumab is a recombinant 
human IgG1 monoclonal antibody specific for TNF-α; it not only inhibits binding of 
TNF-α to its receptors but also lyses cells expressing membrane-bound TNF-α. 
Certolizumab, on the other hand, is a polyethylene glycol (PEG)-conjugated humanized 
anti-TNF Fab fragment. Although anti-TNF-α drugs have been shown to be effective and 
relatively safe for use in treating RA, blockade of this cytokine may have effects beyond 
the suppression of synovial inflammation, which can influence mortality of these 
patients. Mycobacterial infections have been reported among patients undergoing therapy 
with infliximab.193-194 Therefore, tuberculin skin tests and a chest radiograph are usually 
recommended before initiation of anti-TNF treatment. Also, avoidance of anti-TNF 
therapy is recommended for patients with severe chronic heart failure.195 Aside from 
TNF-α, cytokines appear to be of particular importance in the development of RA and, 
therefore, have been investigated as therapeutic targets. Kineret (Anakinra) is a 
recombinant, nonglycosylated form of the IL-1 receptor antagonist (IL-1Ra), a naturally 
occurring receptor antagonist known to counteract the proinflammatory effects of 
interleukins. Patients taking background MTX with anakinra had significant clinical 
improvement as compared to the placebo group.196-197 Simultaneous blockade of TNF-α 
and IL-1 receptor had very promising results in experimental murine arthritis;198 
however, this did not translate well to clinical outcome. Moreover, the risk of 
mycobacterial infections under combination therapy increased significantly; it is 
therefore not recommended for RA treatment.199 Tocilizumab (MRA) is a humanized 
monoclonal antibody against IL-6 receptor (IL-6R). Randomized phase II studies showed 
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that patients receiving tocilizumab had reduced disease activity in a dose-dependent 
manner. 
B lymphocytes play several critical roles in the pathogenesis of rheumatoid arthritis. 
They are the source of rheumatoid factors and anticitrullinated protein antibodies, which 
contribute to the immune complex and complement of T-cell activation in the joints. It is 
therefore assumed that the depletion of B lymphocytes provides a potential therapeutic 
approach to controlling disease activity and inducing remission. This hypothesis has been 
proven in an open-label study of rituximab, a chimeric monoclonal antibody against the 
protein CD20. CD20 is widely expressed on B cells from early pre-B-cells to later stages 
in differentiation, but it is absent on terminally differentiated plasma cells. Rituximab was 
significantly superior to placebo when added to MTX.200 Safety and tolerability of 
rituximab were found to be comparable to that of the placebo. Moreover, there have been 
no higher infection rates under B cell depletion therapy.200  
 
1.3 Blocking Signal-2 
Blocking Signal-2 formation has been shown to alter the immune response via 
induction or anergy of a certain T cell phenotype (i.e. TH1 or TH2). Inhibition of Signal-2 
has been used for the treatment of autoimmune diseases. Monoclonal antibodies and 
peptides (Table 2) that inhibit Signal-2 have been shown to suppress allograft 
rejection,201-202 type-1-diabetes,203-204 rheumatoid arthritis,205-206 and psoriasis.207-208 
Despite the great promise of mAb, these drugs are costly to produce and difficult to 
formulate or deliver. Peptides and peptidomimetics are a better alternative to mAbs.  
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Table 2. Antibodies and peptides that have been investigated for blocking 
Signal-2 in autoimmune diseases, organ transplantation, and cancer 
Signal-2 
Receptor Peptide/Protein Ligand Target Disease References 
Anti-LFA-1 mAb 
(Odulimomab and 
Efalizumab) 
Psoriasis, diabetes, and 
transplantation 
213, 215-218, 
227-228, 242
Anti-ICAM-1 mAb 
(Enlimomab) 
Rheumatoid arthritis, 
diabetes, and 
transplantation 
227, 236-237
Cyclo(1,12)-
PenPRGGSVLVTGC 
(cIBR) 
Rheumatoid arthritis, 
inflammation, and 
immunosupression 
250, 322 
Cyclo(1,12)-
PenITDGEATDSGC 
(cLABL) 
Rheumatoid arthritis, 
inflammation, and 
immunosupression 
250, 252-253
LFA-1/ ICAM-
1 
Cyclo(1,9)-
CLLRMRSIC Inflammation 323 
B7/CD28 Anti-CD28 mAb Transplantation 324 
Anti-CTLA4 mAb 
(Ipilimumab and 
Tremelimumab) 
Melanoma and other 
types of malignancies  292 B7/CTLA-4 
Abatacept (CTLA4-Ig) Rheumatoid arthritis 189 
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Despite progress in designing small molecule inhibitors, a limited number of small 
molecules have been designed to target Signal-2, but none has yet reached the clinical 
setting. 
 
1.3.1 LFA-1/ ICAM-1 interaction 
Studies performed in vivo and in vitro have demonstrated that T-cell activation 
requires interaction of adhesion receptors. Initially, when T cell, encounter APC, 
adhesion receptors physically anchor and provide feedback to the T cells about the 
surface milieu of the APC. This may indeed be followed by TCR signaling and tightening 
of the distance between the two membranes through translocation of the receptors.6, 209 
Adhesion receptors such as ICAM-1 are considered to be involved in intracellular 
signaling, leading to the accumulation of the immune receptors along with MHC 
molecules at the contact area for the efficient presentation of the MHC-p complex to the 
T cells.210 Thus, adhesion is considered a co-stimulatory signal required to generate TCR 
signaling and, further, immune response. There are several adhesion receptors on T cells 
that can deliver a co-stimulatory signal including LFA-1. LFA-1 interacts with ICAM-1, -
2, and -3.210-211 
Efforts made toward understanding the structure, function and mechanisms of 
interaction between LFA-1 and ICAM-1 have produced possibilities of new therapies. 
Currently, several strategies have been developed using LFA-1 and ICAM-1-targeted 
therapeutics, which include antibodies, peptides, peptidomimetics, small molecules, and 
antisense oligonucleotides to suppress LFA-1/ICAM-1 co-stimulatory signal for the 
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treatment of inflammation,212 autoimmune diseases,213 allograft rejection,214-219 and 
cancer.220 The mechanism of action for these antagonists may be very complex. It may 
include binding of the antagonists to either LFA-1 or ICAM-1 for blocking their 
interaction. The antagonist could inhibit or down-regulate the surface expression of the 
receptor or inhibit activation of the receptor.   
 
1.3.1.1 Antibodies 
The role of ICAM-1 and LFA-1 in disease has been studied extensively using anti-
ICAM-1 and anti-LFA-1 monoclonal antibodies. The therapeutic effectiveness of these 
antibodies has been demonstrated in numerous animal models of transplant,221-224 
arthritis,225 insulin-dependent diabetes mellitus,226-229 multiples sclerosis,230-234 and 
lupus.235 The first LFA-1/ICAM-1-targeted monoclonal antibody tested clinically was 
anti-LFA-1 antibody Odulimomab (antibody 25.3) in bone marrow215, 218 and kidney 
transplant,216-217 while anti-ICAM-1 antibody Enlimomab (antibody R6.5 or BIRR1) has 
been investigated in kidney transplant236 and rheumatoid arthritis.237 Anti-ICAM-1 
antibody is progressing through phase I and II trials for the treatment of rheumatoid 
arthritis.238 Blocking ICAM-1/LFA-1 interaction using Enlimomab failed to show any 
benefit in a randomized renal transplantation study.239 A recombinant humanized 
monoclonal antibody that binds to CD11a (the -subunit of LFA-1), efalizumab has been 
successfully used in the treatment of psoriasis.213, 240-247 Recently, a crystal structure of 
the efalizumab Fab in complex with the LFA-1 I-domain reveals that the antibody binds 
to the I-domain distinct from the ICAM-1 binding site and blocks the binding of LFA-1 
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to ICAM-1 via steric hindrance.248 Efalizumab, under the trade name Raptiva has been 
approved by the FDA in 2003 for the treatment of moderate-to-severe plaque psoriasis, it 
has been withdrawn from the market because of increased patient susceptibility to 
PML.249 Although monoclonal antibodies such as Efalizumab successfully demonstrated 
their ability to induce tolerance, increased risk for secondary infections, immunogenicity, 
and lesser clinical efficacy limited their therapeutic use. Hence, alternative molecules 
such as peptides and small molecules are being developed for their utility in 
immunotherapy; these offer distinct advantages in terms of safety and development and 
treatment costs.  
 
1.3.1.2 Peptides 
The Siahaan group has discovered several cell adhesion peptides that block LFA-
1/ICAM-1 interaction (Signal-2). These peptides were derived either from domain-1 of 
ICAM-1 or - and -subunits of LFA-1. The peptides derived from ICAM-1 and LFA-1 
are listed in Table 2. Studies done using in vitro cellular models such as homotypic or 
heterotypic T cell adhesion or mixed lymphocyte reaction have clearly demonstrated the 
ability of these peptides to inhibit the binding of T cells to APC by blocking the binding 
of adhesion receptors to their natural ligands.250-256 However, in vivo administration of 
these molecules for suppression of autoimmune diseases without general immune 
suppression is absolutely critical, as blocking Signal-2 may also create a general 
suppression of T-cell activation that may lead to increased susceptibility to secondary 
infections. 
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1.3.1.3 Antisense oligonucleotides 
ICAM-1 is constitutively expressed by several cell types including endothelial and 
epithelial cells and is upregulated during many pathological conditions such as 
inflammation and autoimmune diseases. Alicaforsen (ISIS 2302), an antisense 
oligonucleotide, has been designed to specifically block ICAM-1 synthesis.  Alicaforsen 
binds to the RNA molecule and further blocks the translation of the ICAM-1 protein 
within the cell.257-258 The clinical outcome of Alicaforsen was assessed in several 
randomized controlled phase II and III trials for the treatment of Crohn’s disease and 
ulcerative colitis. Initial trials involving a small group of subjects have shown promising 
results for both diseases, but later larger trials failed to meet the clinical efficacy tests.259-
265 Similar results were obtained in the rheumatoid arthritis study, and no significant 
difference was found between placebo- and ISIS 2302-treated groups, even though the 
drug was well tolerated.266 
 
1.3.2  CD28/B7 interaction 
CD28/CTLA-4:B7 interactions (Fig. 2) provide critical co-stimulatory signals 
required for complete T-cell activation. Molecules designed to block CD28/CTLA-4:B7 
interactions have been widely investigated for immunotherapeutic strategies to regulate 
autoimmune diseases as well as response to transplantation.267-270 It has been suggested 
that inhibition of the co-stimulatory signal via the CD28 pathway is more desirable 
because CTLA-4:B7 interactions have been shown to participate in the extinction of the 
T-cell receptor-mediated activation signal and induction of immunotolerance. The signal 
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transmitted through CTLA-4 leads to dephosphorylation of the second messengers in the 
CD3 complex and subsequently leads to control of the production of various cytokines 
produced by TH1 and TH2 cells.271-272 Moreover, CTLA-4 has been implicated in the 
development of Treg cells in several models of organ transplantation,273 and CTLA-4-
deficient animals have been shown to be resistant to immunotolerance.274 However, 
selective CD28 inhibition decreases the activation of alloreactive and autoreactive T cells 
but not the activation of T cells stimulated by exogenous antigens presented in the 
context of self MHC. Antibody-induced modulation of co-stimulatory signal via CD28 
pathway has been shown to prolong allograft survival in rats.275 Similarly, administration 
of anti-CD28 Fab fragments efficiently led to suppression as well as reversal in the 
induction of EAE276 and uveoretinitis277 in mice. In CD28-deficient mice, immune 
responses to viral antigens or autoantigens are impaired,278-279 whereas responses to 
exogenous antigens remain normal,280 suggesting that T cell responses to autoantigens or 
alloantigens are more dependent on the costimulation through CD28 than on T cell 
responses to exogenous antigens. Thus, blockade of CD28 may be a better target for 
immunosuppression for the selective inhibition of pathologic T cells in autoimmunity and 
transplantation without inhibition of other protective T cell responses. CD28 blockade 
cannot be achieved with anti-CD28 dimeric antibodies because of target clustering, which 
promotes T cell costimulation.281-282 So far, all antibodies investigated against human 
CD28 are indeed agonists. Conversely, monovalent fragments can block CD28/B7 
interactions without stimulating CD28282 but, in spite of all this potential, fab fragments 
cannot be used therapeutically in vivo because of their rapid elimination from the body. 
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Conjugation to both polyethylene glycol and molecular fusion with serum albumin, 
however have been investigated to improve the stability of these molecules and thereby 
extend their half-lives in the body. 
Several studies have shown that selective blockade of CD28:B7 interaction using 
anti-CD28 Fab administration significantly ameliorated EAE.276, 283 It is thought that 
amelioration could be largely or in part due to ablation of TNF-α production.276 TNF-α 
has been associated with encephalitogenicity.284-285 It is thought that T cell infiltration 
into the CNS, together with TNF-α inhibition, led to suppression of EAE.285 However, 
results from recent studies have shown that EAE can be induced in mice deficient in 
lympotoxin-α and TNF-α, suggesting that other cytokines can replace their central 
pathogenic role in EAE.286 Although CD28 blockade using mAb attenuated EAE and 
prevented subsequent relapses, it did not completely eliminate the encephalitogenic 
response, suggesting that activation of encephalitogenic T cells independent of CD28 
costimulation may not have been completely abolished. This observation is consistent 
with findings in CD28-deficient mice. CD28-/- mice developed autoimmune heart 
disease, although it was less severe than that observed in heterozygous littermates.278 
Similarly, breeding NOD mice with CD28-/- was found to exacerbate autoimmunity.287 
All these taken together suggest that inhibition of CD28 costimulation using anti-CD28 
Fab and suppression of autoimmunity may be at least partially dependent on T cell 
costimulation. It is also plausible that CD28 inhibition may prevent further recruitment 
and activation of naïve T cells and therefore interfere with epitope spreading. 
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1.3.3 CTLA-4/B7 interaction   
Anti-CTLA-4 monoclonal antibodies can block the interaction between CTLA-4 and 
B7, there by blocking the inhibitory signal sent by CTLA-4.  It is hypothesized that this 
blockade improves the ability of cytotoxic T cells to respond better to antigen 
presentation by APC, thus enhancing the activation and proliferation.  In this section, 
several studies conducted on the effect of anti-CTLA-4 on autoimmune diseases such as 
EAE and lupus will be discussed as well as the efficacy of anti-CTLA-4 mAb treatment 
in tumor therapy.  
The effects of inhibiting the CTLA-4/B7 interaction were studied in the mouse EAE 
model using hamster anti-mouse CTLA-4 mAb.288  This study has shown that a single 
injection of anti-CTLA-4 two days post-immunization in mice resulted in a mild increase 
in severity and incidence of EAE.  In another experiment, anti-CTLA-4 was administered 
on the second day after clinical signs of EAE were observed and then every other day for 
the following 6 days.  In this case, there was a marked increase in the disease score and 
several of the mice injected with the anti-CTLA-4 died. Also, there was a considerable 
increase in the production of IL-2, TNF-α, and IFN-γ; EAE is usually accompanied by an 
increase in the production of these cytokines.289   
Similar conclusions were drawn from another study.290 In addition to the increase in 
the severity of the disease, histological studies showed more inflammatory foci in the 
brain and the spinal cord of the mice treated with the anti-CTLA-4 compared to the 
control antibody-treated mice.  The authors concluded that blocking the inhibitory signal 
by CTLA-4 possibly resulted in enhanced activation and proliferation of antigen-reactive 
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T cells.  The authors also stated that the exact mechanism of this improved activation is 
unclear and suggested that it was due to the lowering of the activation threshold of the T 
cells. The data from these studies showed that anti-CTLA-4 interfered with the CTLA-
4/B7 interaction and prevented the inhibitory signal from being properly delivered, which 
led to enhanced T-cell activation and, consequently, more severe clinical disease. Both 
the studies suggest that CTLA-4 blockade is not a good approach for the treatment of 
autoimmune diseases, but they showed the importance of the CTLA-4/B7 interaction in 
these autoimmune diseases.  
CTLA-4 blockade may show promise in the treatment of cancer.  
Immunosurveillance is a process in which the body protects itself from developing 
tumors.  Unfortunately, in some individuals, the activation of the tumor-killing T cells is 
suppressed and, therefore, lowers the effectiveness of immunosurveillance.291  It is 
believed that if the inhibitory signal sent by CTLA-4 is blocked by the anti-CTLA-4 
antibody, the T cells can be activated and fight the tumors.  Recently, several clinical 
trials have been conducted using the anti-CTLA-4 antibody to try to treat melanoma and 
other types of malignancies (Table 2).  Two of these antibodies, ipilimumab and 
tremelimumab, have reached phase III clinical trials.292 
1.4 Bifunctional peptide inhibitors 
Recently, we have discovered a novel and selective method to suppress autoimmune 
diseases using bifunctional peptide inhibitor (BPI) molecules that simultaneously target 
both Signal-1 and Signal-2 (Fig. 4). Results from our studies have demonstrated that two 
different BPI molecules (i.e., PLP-BPI and GAD-BPI) can induce immunotolerance in 
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autoimmune diseases in two different animal models, EAE293-294 and NOD mice.161  In 
addition to these two BPI molecules, we also have ongoing and promising studies toward 
developing similar molecules to treat collagen-induced arthritis in DBA/1J mice, a mouse 
model for rheumatoid arthritis. In the case of PLP-BPI, the antigenic-peptide epitope 
derived from the proteolipid protein (PLP139–151) was conjugated to LABL peptide 
derived from αL integrin (CD11a237–246) to make BPI molecules.293-294 GAD-BPI is made 
from GAD208-217 and LABL peptides. We hypothesize that the antigenic peptide fragment 
(i.e., PLP139-151 and GAD208-217) binds to MHC-II and the LFA-1 peptide fragment 
(LABL) binds to ICAM-1 on the surface of APC. Because both peptides are conjugated 
via a linker, simultaneous binding of BPI to MHC-II and ICAM-1 will prevent the 
translocation between TCR:MHC-II-peptide (Signal-1) and ICAM-1/LFA-1 complexes 
(Signal-2) that forms the immunological synapse. Inhibition of immunological synapse 
formation selectively alters the activation of T cells from TH1 to TH2 phenotypes and/or 
induces the production of Treg cells. Because these BPI molecules contain specific 
antigenic peptides, we hope that we can target only a specific subpopulation of T cells 
involved in the onset and progression of autoimmune diseases without affecting the 
general immune response.  
Studies with experimental models of autoimmune disease and allergy have shown that the 
administration of soluble peptides based on known T cell epitopes leads to suppression of 
the specific response, induction of bystander suppression, and prevention and treatment 
of hypersensitivity. Injections of antigenic peptides such as PLP139-151269, 295 and GAD208-
217
296 in saline have been shown to suppress the progression of EAE and 
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APC
T cell
TCR/CD4
MHC-II
LFA-1
ICAM-1
Signal-2 Blocker Antigenic Peptide
BPI
Figure 4. The proposed binding of the BPI molecule to MHC-II and ICAM-1, which 
inhibits the translocation of Signal-1 and Signal-2.
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T1D, respectively, in mice models. However, treatment with antigenic peptides is 
potentially dangerous and can lead to fatal anaphylactic reactions. Many researchers have 
modified these antigenic peptides via mutation297 or development of altered peptide 
ligands (APL)298 in an effort to improve their therapeutic potential in treating 
autoimmune diseases as well as address their safety concerns.  
Our data showed that PLP-BPI has better activity in suppressing EAE than do other 
peptides, including VP2-BPI (a BPI with an epitope peptide derived from Theiler’s 
encephalomyelitis  virus capsid protein, VP274-86), which is known to bind to MHC-II in 
SJL/J mice,299 PLP-BPIsLABL (PLP-BPI with a scrambled sequence of LABL), OVA-BPI 
(BPI in which PLP139-151 has been replaced with OVA326-337 derived from ovalbumin), 
and the unlinked mixture of PLP139-151 and LABL. PLP-BPI-treated mice had very low 
EAE clinical scores and minimal loss in body weight compared to other groups. In 
addition, some of the PLP-BPI-treated mice did not develop the disease.293-294 Similarly, 
dosing regimens designed for therapeutic treatment instead of prophylactic treatment 
showed that BPI was able to reverse disease severity very quickly.294 Some of our 
unpublished work shows that PLP-BPIsPLP (PLP-BPI with a scrambled sequence of 
PLP139-151) has no EAE-suppressing activity, suggesting the significance of a unique 
structure in PLP-BPI such as the need for both PLP139-151 and LABL peptides and 
covalent linking of these two peptides in the same molecule. Also, more importantly, we 
found out that these molecules are highly antigen-specific. We observed that splenocytes 
isolated from PLP139-151-immunized mice responded to in vitro re-stimulation with 
PLP139-151 but not MBP87-89 and vice versa.294 It was also interesting to find that 
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splenocytes isolated from Ac-PLP-BPI-NH2 (a modified form of PLP-BPI) showed 
significantly less proliferation in re-call to PLP139-151, suggesting that injection of Ac-
PLP-BPI-NH2 reduces and/or suppresses the number of PLP139-151-responsive 
populations. In a parallel study, GAD-BPI had the capacity to suppress the progression of 
T1D in NOD mice as demonstrated by significantly less insulitis and lower blood glucose 
levels in GAD-BPI-treated mice compared to control.161 
Another important issue we looked at is the safety of these BPI molecules. As with 
any other peptide-based therapy, there is an associated risk involved in the use of BPI 
such as the possibility of an anaphylactic response, a life-threatening immediate 
hypersensitivity reaction caused by injections of the antigen-related peptides. Due to 
hypersensitivity reactions in patients during phase II clinical trials, development of an 
MS-targeted peptide drug was suspended.300-301 In our studies, intravenous injection of 
PLP-BPI at four-to-five weeks post-immunization caused anaphylactic reaction to a much 
lower number of mice than does PLP139-151. Additionally, a modified form of PLP-BPI 
(i.e., Ac-PLP-BPI-NH2-2 with a longer linker and its N- and C-terminal acetylated and 
amidated, respectively) was found to be even less aggressive in inducing anaphylactic 
reactions.294 We speculate that the lower incidence of anaphylaxis in BPI is due to the 
presence of LABL peptide that inhibits LFA-1/ICAM-1 interactions at the site of antigen 
recognition or the addition of another moiety at the N- or C-terminal to the parental 
allergic peptide PLP139-151. Involvement of LFA-1/ICAM-1-mediated heterotypic 
aggregation of activated T cells to mast cells has been implicated in augmenting mast cell 
degranulation and histamine release.302 
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1.5 Peptide Safety 
A potential problem that can arise when treating diseases with multiple injections of 
antigen-related peptides is the possibility of anaphylactic shock.297, 303 Due to the fact that 
peptides are smaller in size than proteins, it is thought that they are safer and less likely to 
induce an anaphylactic response in the immune system.  Despite the numerous 
advantages of peptides over proteins, anaphylactic reactions during treatments involving 
peptides have been widely described in the literature.293, 297, 303 
In general, the mechanism of anaphylactic response is thought to occur when an 
antigen crosslinks with IgE bound to FcεRI on mast cells, which leads to degranulation 
and the release of histamine and cytokines, both of which are inflammatory mediators.302  
The administration of anti-IgE antibodies along with myelin-specific peptides during the 
treatment of EAE has been shown to inhibit anaphylaxis, which suggests that IgE plays a 
large role in anaphylaxis when treating with peptides.304  
APL have been shown to suppress anaphylaxis in EAE without affecting its activity 
toward myelin-reactive T cells.305 Short linear peptide sequences generally lack the 
ability to crosslink adjacent IgE molecules on mast cells and basophils.306 Because a non-
immunogenic peptide sequence can become immunogenic when only one of its amino 
acid residues is altered, care must be exercised in designing an APL so that it retains its 
activity toward its target and does not become more antigenic.  
The avoidance of IgE activation is necessary to circumvent allergic response. It is 
optimal to use peptides shorter than 20 amino acids, as longer peptides have been 
associated with more adverse events compared to their shorter counterparts.306 Five-to-six 
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amino acids have been shown to be sufficient minimal antigenic determinants.307 
Alternatively, APL that can bypass the body's ability to create an anaphylactic response 
against a peptide without affecting its activity toward its target have been shown to work 
and must be utilized in creating effective therapies. 
 
1.6 Mechanism of peptides that treat autoimmune diseases 
It has been described before that the immune system functions as a balance between 
pathogenic effector cells and regulatory cells.306  The suppression and activation of these 
two will lead to either an immunogenic response or an immunotolerant response (Fig. 5).  
Autoimmune diseases typically arise due to an imbalance between these two responses.  
Therefore, to combat autoimmune diseases, we must try to restore balance in the immune 
system.   One way to restore the balance is by either inducing the suppressive cells or 
activating the regulatory cells. 
DCs are considered to be the most prominent APCs in inducing an autoimmune 
disease.  They are believed to send a “danger” signal to induce an immunogenic response, 
but that is not always the case.308  The function of the DC depends on whether it is in a 
mature (activated) or immature state.309 The maturation of DC into a T cell stimulatory 
mode is activated by an inflammatory stimulus that is initiated by the uptake of an 
insoluble antigen (Fig. 5, left side).306, 309  Once the DC is in the mature state, its 
phenotype changes and there is an upregulation of co-stimulatory and adhesion molecule 
expression on its cell surface.  Presentation of antigen in this way leads to the 
differentiation of proinflammatory cellular responses.306  Such an inflammatory cellular 
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response triggered by a mature DC (mDC) includes the induction of TH1 cells that 
produce IFN- and IL-2.309  Other proinflammatory responses include the induction of 
TH17 and the release of IL-17.135  These inflammatory responses triggered towards self 
tissues usually lead to an autoimmune disease such as multiple sclerosis. 
On the other hand, an immature DC (iDC) is one that did not take up and process any 
antigens. It has been shown, using antibodies specific for peptide-free MHC-II molecules 
that iDC express empty MHC-II molecules, on their surface and can bind antigenic 
peptides in solution.  These bound antigens can be presented to T cells without 
internalization and processing.310  Soluble peptides that are presented by iDC lead to a 
differentiation of Treg cells (Fig. 5, right side).306  Activation of regulatory T cells leads to 
the production of regulatory cytokines such as IL-10 and TGF-β.  Such cytokines have 
been shown to have an important role in ameliorating autoimmune diseases in animal 
experimental models.311-313 In the case of some autoimmune diseases, expanding the 
“regulatory pool” leads to a downregulation of the effector response (TH1) and 
enhancement of the immunosuppressive response (TH2).306 
 
1.7 Proposed BPI mechanisms 
There are several possible mechanisms that could explain how BPI molecules suppress 
the activation of T cells and result in suppression of autoimmune diseases. The first of 
these is that only the antigenic fragment of BPI molecule binds to MHC-II on the iDC 
(steady-state DC) and is presented to naïve T cells for differentiation to produce Treg cells 
that generate IL-10 (Fig. 6, right side). This proposed mechanism, which is similar to the 
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mechanism of action of soluble antigenic peptide as a therapeutic vaccine,306 ignores the 
role of cell adhesion peptide (e.g., cIBR or LABL) on the BPI molecule. It has been 
shown that injection of the BPI molecules generates IL-10293; however, the kinetics and 
the amount of IL-10 production upon BPI and PLP peptide injections have not been 
compared. Because the BPI molecule has better efficacy than the parent antigenic peptide 
(PLP),293 it is predicted that the amount of IL-10 produced by injecting BPI molecules 
will be higher than that produced by injecting PLP peptide. The second possible 
mechanism is that the BPI molecule binds not only to MHC-II but also to adhesion 
molecules (e.g. LFA-1 or ICAM-1) on iDC. Thus, during the interaction between BPI-
loaded iDC and naïve T cells, the BPI molecule blocks the immunological synapse 
formation to induce differentiation of naïve T cells to Treg cells. The presence of cell 
adhesion peptide on BPI makes it a more efficient modulator for naïve T cell 
differentiation than the antigenic peptide alone. The third possible mechanism is that the 
BPI molecule simultaneously binds to MHC-II and LFA-1 to block the immunological 
synapse formation during the interaction between naïve T cells and mDC (Fig. 6, left 
side) to suppress the differentiation of naïve T cells to TH1 and TH17 cells. There is some 
indication that the BPI molecule induces the generation of IL-4-producing TH2 cells, 
which may tip the balance to lower the production of TH17 and TH1 cells. The increase in 
IL-4 production was observed after BPI injection into the EAE mouse model.293  The 
mechanism of action of BPI molecules may also be a combination of these three 
proposed mechanisms.  
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1.8 Conclusions 
Immunomodulating compounds have been explored as potential treatments for 
autoimmune diseases such as MS, T1D, and RA among others. However, most of the 
agents developed thus far aim at broad modulation of the immune response and, 
therefore, may present some undesirable side effects. Targeted drug delivery is a more 
attractive strategy to improve the efficacy and reduce the side effects of these 
immunomodulating drugs. In our studies, we hope to design bifunctional peptide 
inhibitors that target only a subpopulation of T cells responsible for the progression of the 
disease without affecting the general immune response. Although it has not been clearly 
elucidated, BPI-based therapies work either by inhibiting the formation of the 
immunological synapse by blocking both Signal-1 and Signal-2 or shifting the T cell 
subpopulation into Tregs and/or TH2-like phenotype. The detailed mechanisms of action of 
BPI-type molecules, including the antigen-specific immunosuppressive activity as well as 
its safety, are being investigated in depth in our current studies. Additionally, we are 
looking at ways of improving the structure and sequence of BPI to provide a more 
efficient and well-tolerated immunotherapy. 
 
1.9 Objectives and specific aims 
One way to improve the structure of the BPI molecule is by substituting the cell 
adhesion peptide with a cell adhesion protein. For example, the original PLP-BPI 
molecule contains an antigenic-peptide epitope, PLP139–151, and a cell adhesion peptide, 
LABL. The LABL peptide derived from the I-domain of αL integrin (CD11a237–246) is 
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known to bind to ICAM-1 receptors. Thus, LABL can be replaced with the I-domain, to 
make a conjugate between I-domain and PLP (PLP-I-domain). The hope is that the PLP-
I-domain will have improved efficacy, safety, and tolerability. In addition, I-domain can 
also be used to deliver multiple antigenic peptides. Hence, the overall objective of this 
work is to investigate the utility of the I-domain protein in delivering antigenic peptides 
to antigen presenting cells for suppressing EAE in mouse model. Therefore, the following 
specific aims were pursued:  
 
Specific Aim 1: To conjugate a fluorescent dye (FITC) to the N-terminus and/or lysine 
residues of the I-domain protein to produce FITC-labeled I-domain. To characterize the 
conjugate and identify the FITC-modification sites in the FITC-I-domain protein using 
LC ESI-Q-TOF mass spectrometry. 
 
Specific Aim 2: To examine the binding and internalization properties of the FITC-I-
domain protein, mediated by ICAM-1 receptors on the surface of lymphocytes. 
 
Specific Aim 3: To conjugate PLP to the N-terminus and/or lysine residues of the I-
domain protein to produce PLP-I-domain and evaluate its in vivo suppression of EAE. 
The above specific aims are addressed in chapter 2, 3, and 4 respectively.  
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CHAPTER 2 
Rapid Identification of Fluorochrome Modification Sites in Proteins by LC ESI-Q-
TOF Mass Spectrometry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101
2.1 INTRODUCTION 
Proteins (including antibodies) are modified with fluorochromes to maximize 
sensitivity in binding assays or cell imaging.  Fluorescein and rhodamine are the most 
commonly used fluorochromes because of their high quantum yields.  The modification 
of proteins by either fluorescein-5-isothiocyanate (FITC) or rhodamine-B-isothiocyanate 
(RITC) is a well-established method.1 Protein labeling is done by reacting the 
isothiocyanate group of the fluorescent dye with the primary amines and thiol groups of 
proteins to yield thiourea or dithiourethane adducts.2  Frequently, the reaction product 
between a protein and an activated dye is a heterogeneous mixture of conjugates that 
differ in the number of fluorochromes attached to the protein. Identification of modified 
sites on the protein is often a laborious process and is challenging because of the 
heterogeneity of the sample and low abundance of the modified residues. However, it can 
be critical to determine the modified sites, as the affinity of the protein to its ligand may 
be altered by modification of critical residues in the binding site or alteration of the 
protein conformation. 
Lymphocyte function-associated antigen-1 (LFA-1) belongs to an integrin receptor 
family that is composed of heterodimeric - and -subunits. The -subunit of LFA-1 has 
an inserted domain (I-domain), which serves as the primary binding domain for 
intercellular adhesion molecule-1 (ICAM-1). The I-domain protein has been expressed 
and is well characterized. The metal ion-dependent adhesion site (MIDAS) of this I-
domain interacts with a glutamate residue of domain 1 (D1) of ICAM-1.3-4, 5 It has been 
shown that the cell surface expression of ICAM-1 is upregulated during several 
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pathological conditions, including cancers, inflammation, and autoimmune diseases 
(multiple sclerosis,6-8 rheumatoid arthritis,9 type 1 diabetes,10 and lupus11). Thus, our goal 
is to utilize the I-domain to target small molecule drugs to cells with upregulated 
expression of ICAM-1 protein for lowering side effects.  
In this study, the I-domain was conjugated with fluorescein and rhodamine 
fluorophores at lysine residues and the N-terminus (Fig. 1). The I-domain has 20 lysine 
residues that can be modified by fluorophores, and the condition for the conjugation 
reaction was optimized to introduce an average of three to four fluorescein molecules per 
I-domain molecule or two to three rhodamine molecules per I-domain molecule. It is 
essential to determine the sites of modification on the I-domain because the modification 
may influence the binding and internalization properties of I-domain. Modification of the 
MIDAS region could render the protein inactive or unable to bind to ICAM-1. 
A combination of tryptic digest and mass spectrometry was used to identify the 
conjugation sites of the fluorophores because it is a sensitive and flexible method for the 
characterization of modified peptides. The fluorescein thiocarbamoyl modification has 
been detected by mass spectrometry since the early use of soft ionization, thermospray, or 
chemical ionization to detect phenyl thiohydantoin (PTH) derivatives of amino acids, the 
result of phenyl isothiocyanate (PTC) coupling to amines.12 While the focus of this early 
work was differentiating between the amino acids in the classic Edman degradation, the 
spectra also presented a “reporter ion” of the modifying group. The reporter ion is readily 
generated in an electrospray ionization quadrupole time-of-flight (ESI-Q-TOF) 
instrument such that the modified peptides can be found and their identity can be 
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Figure 1. (A) Schematic representation of a single-step modification of I-domain protein 
with FITC. (B) Illustration of chemical structures of FITC and FTC-I-domain.
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confirmed. This strategy of using fragmentation in the collision cell of a Q-TOF without 
explicit MS/MS has been exploited in the fatty acid analysis of complex lipids analysis13 
and provides the fundamental data used in MSE by WATERS for proteomics.14 
Previously, Schnaible and Przybylski demonstrated the possibility of the identification of 
fluorescent dye modified sites by increasing the declustering potential (so called “cone” 
fragmentation) in the electrospray ion (ESI) source to generate a reporter ion from the 
dye on a peptide.15 This specific fragmentation was utilized for assigning the fluorescent 
dye modification sites in peptides obtained from enzymatic digestion of fluorescein-
modified hen egg white lysozyme (HEL).  In the present study, we used ESI-Q-TOF MS 
to readily generate these reporter ions in the collision cell of the Q-TOF and, along with 
LC/MS, expand the earlier observations of Schnaible and Przybylski to assess the 
fluorochrome distribution and determine the fluorescent dye conjugation sites in the 
modified I-domain after trypsin digestion.  
 
2.2 MATERIALS AND METHODS  
 
2.2.1 Materials  
Fluorescein-5-isothiocyanate (FITC) isomer I, rhodamine-B-isothiocyanate (RITC) 
mixed isomers, and other solvents and reagents of highest available purity were 
purchased from Sigma-Aldrich (St. Louis, MO). Sequence-grade modified trypsin was 
purchased from Promega (Madison, WI).  
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2.2.2 Peptide synthesis and purification 
The model peptides cyclo(1,12)Pen-ITDGEATDSGC (cLABL) and cyclo(1,12)Pen-
PRGGSVLVTGC (cIBR) were synthesized as linear peptides by standard Fmoc solid-
phase peptide chemistry using the automated peptide synthesis system (Pioneer 
PerSpective Biosystems, Framingham, MA) as described elsewhere.16 The synthesis 
product was purified by HPLC followed by cyclization and purification as previously 
described.16 The molecular weight of the peptide was confirmed by electrospray 
ionization mass spectrometry (M + 1 = 1174.5 for cIBR and 1197.25 for cLABL). 
 
2.2.3 Fluorochrome modification of the peptides 
Conjugation of FITC with cLABL was carried out using the procedure previously 
published by our laboratory.17 Briefly, pure peptide (0.04 mmol) was dissolved in 5 mL f 
Nanopure water and FITC (0.08 mmol) was added. The pH of the solution was adjusted 
to 10 by addition of a 1.0 N NaOH solution. The solution was stirred for 1 h with a 
magnetic stirrer. After completion of the reaction time, the reaction mixture was 
neutralized by the addition of a 10% v/v acetic acid solution. The solution was 
lyophilized. The lyophilized crude peptide was then purified by semi-preparative C18 
reversed-phase HPLC. The pure fractions of the peptide were pooled and lyophilized. 
The lyophilized FITC-peptide was analyzed by analytical C18 reversed-phase HPLC for 
its purity, and its identity was confirmed by ESI-MS (M+1). Conjugation of rhodamine 
with cIBR was done in a manner identical to that described above with the exception that 
FITC was replaced by RITC. 
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2.2.4 LFA-1 I-domain protein expression and fluorochrome modification  
The LFA-1 I-domain protein (residues 128–307, plus an additional N-terminal 
methionine) was expressed, refolded, and purified as previously described.18 Briefly, the 
expression vector pET-11d containing the gene of LFA-1 I-domain128-307 was used in E. 
coli BL21 (Stratagene, La Jolla, CA) competent cells, where the protein was found in 
inclusion bodies. The protein was purified and refolded as previously described.18 The 
identity was confirmed by mass spectrometry.   
The procedure for conjugation of fluorescent dyes (FITC/RITC) with the I-domain 
protein was adopted from the previously published method with some modifications.1 To 
a total of 6.0 mg of the I-domain in PBS containing 10 mM MgSO4, a one-fourth volume 
of 1.0 M NaHCO3-Na2CO3 buffer at pH 9.0 was added. FITC (5 mg/mL in DMSO) was 
added to the protein solution to a 25-fold molar excess over the I-domain with a final 
concentration of 1.5 mg/mL. The reaction was carried out for 2 h at 25 °C in the dark 
with constant stirring. The reaction was quenched with addition of 0.1 N HCl. Separation 
of the free dye from dye-coupled protein was done using a Superdex 200 size-exclusion 
column. The fractions belonging to the conjugated protein were collected and 
concentrated using an ultrafiltration device. The concentrated protein was filtered using a 
0.2-micron filter and stored at 4 °C.  Modification of I-domain with rhodamine was done 
in a manner identical to that described above with the exception that a 25-fold molar 
excess FITC was replaced by a 20-fold molar excess of RITC. The number of FITC or 
RITC groups conjugated to the I-domain protein was determined by electrospray mass 
spectrometry.  
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2.2.5 In-gel tryptic digestion and LC ESI-Q-TOF mass spectrometry analysis 
100 μg of protein was run on a polyacrylamide gel followed by Coomassie blue 
staining. The stained gel spot of interest was excised and cut into smaller pieces for better 
solvent penetration into the gel. Then, the gel pieces were transferred to a clean 
microcentrifuge tube, washed twice with a solution containing a 1:1 mixture of 
acetonitrile and 50 mM ammonium bicarbonate buffer at pH 8.0 for 45 min at 37 °C with 
gentle agitation. After discarding the washing solution, the gel pieces were shrunk with 
250 μL of neat acetonitrile. After 10–15 min the residual solvent was discarded, and the 
gel pieces were dried completely. The gel pieces were re-swelled with 40 μL of digestion 
buffer A (0.2 M ammonium bicarbonate buffer at pH 8 and 5 mM CaCl2) containing 2 μg 
trypsin. Then, 50 μL of the digestion buffer B (0.2 M ammonium bicarbonate buffer at 
pH 8 and 10% acetonitrile) was added to keep the gel pieces immersed throughout the 
digestion. The digestion was carried out overnight at 37 °C, and the reaction was stopped 
by the addition of 0.1% formic acid. The gel pieces were sonicated and the supernatant 
containing the digested peptides was collected as primary sample fraction and analyzed 
by LC ESI-Q-TOF MS. 
All HPLC separations were performed with a Water Acquity solvent delivery system 
using a binary gradient of solvent A composed of 98.92:1:0.08 H2O/formic acid/TFA 
(vol/vol/vol) and solvent B containing 98.92:1:0.08 acetonitrile/H2O/formic acid 
(vol/vol/vol). The primary sample fraction (20 μL) containing the digested peptides was 
separated on a C4 (5 cm × 1 mm i.d.) reversed-phase HPLC column (VM5C4W, packed 
by Micro-Tech Scientific, Vista, CA) with a linear gradient from 10% to 70% B in 60 
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min followed by a wash and re-equilibration step. Further, the HPLC system was coupled 
online to the electrospray source of a Q-TOF-2 mass spectrometer (Micromass UK Ltd., 
Manchester, UK). Mass spectra were acquired with instrument cone voltage 35 eV, 
collision energy 10 eV with Ar in the collision cell.  The instrument was set up such that 
ESI-MS spectra were acquired in positive reflector mode with a scan time of 6 s and in 
the mass range of 200-3000. The instrument was calibrated using NaI.  
 
2.2.6 Analysis of the peptide fragments 
The reporter ion chromatograms were processed for molecular weight of the peptides 
using MaxEnt3 in the MassLynx V4.1 software (Micromass UK Ltd.) to reduce the 
spectral complexity to single charge representation. A theoretical list of all the possible 
peptides as a result of tryptic digestion of the protein and their corresponding masses was 
generated by BioLynx. Each peptide fragment peak identified in the chromatograph was 
manually compared with peptide mass from the theoretical list.  
 
2.3 RESULTS 
2.3.1 Analysis of I-domain conjugates by ESI-MS: 
The I-domain protein was modified with fluorescent dye (FITC or RITC) in an 
aqueous buffer solution using a molar ratio of fluorescent dye:I-domain of 25:1 or 20:1 
for 2 hrs at 25 °C at pH 9.0 as shown in Fig. 1. Under such conditions, the isothiocyanate 
group of the fluorescent dye preferentially reacts with primary amino and thiol groups on 
proteins forming stable thiourea and dithiourethane adducts. Because the I-domain does 
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not contain any cysteine residues, it is expected that only a thiourea adduct is formed. 
After removal of the unreacted fluorescent dye by SEC, the number of conjugated FITC 
molecules was ascertained using ESI-Q-TOF MS. The deconvoluted spectrum shows 
seven prominent peaks (Fig. 2). Each adjacent peak is separated by a mass difference of 
388 Da to 390 Da with a mean of 389 Da. This consistent mass difference between the 
adjacent peaks in the spectra is due to the covalent link of the FITC group (molecular 
weight 389.4 Da) on the I-domain protein. The mass of the first peak in the series is 
21,072 Da (1F, one fluorescein), which is associated with I-domain conjugated with one 
FITC molecule. The parent I-domain protein has a molecular weight of 20,682 Da (0F, 
no fluorescein). In this case, the associated error is less than 0.01%, which is typical for 
such mass measurements. The rest of the peaks can be assigned to the I-domain 
conjugated with two, three, four, five, six, and seven covalently linked FITC (2–7F) 
molecules, respectively. The spectrum also shows the disappearance of the peak for the 
parent I-domain (0F), indicating a complete conversion. A similar analysis done using 
RTC-I-domain shows 0–4 covalently linked RITC molecules (data not shown). 
 
2.3.2 Analysis of model peptide conjugates by ESI-MS: 
Before analyzing the tryptic-digest products of I-domain conjugates, the fragmentation 
profile of peptide-conjugated with fluorescent dye was first investigated using Q-TOF 
mode. cLABL peptide was reacted with FITC at the N-terminus to give FTC-cLABL, 
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Figure 2. Deconvoluted mass spectrum of FTC-I-domain. The modification of one FITC 
molecule to either lysine or N-terminus amino group increases the theoretical mass of the 
I-domain protein by 389 Da. F, is the number of FITC molecules conjugated.
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and cIBR peptide was reacted with RITC to produce RTC-cIBR. After the HPLC 
purification, the pure FTC-cLABL or RTC-cIBR was used for ESI-MS analysis.  
Under the conditions employed, the presence of the reporter ion (i.e., free dye molecule) 
was detected. In this case, several fragments were detected, including the free dye (i.e., 
FTC, m/z = 389.98 or RTC = m/z of 500.26), the parent peptide, and the modified 
peptide. Free fluorescent dye molecules were facile at lower energy and were readily 
generated. By following the reporter ion, the peptide fragments attached to the 
fluorescent dye can be identified. These results suggest the possibility of identifying the 
conjugation sites in I-domain protein by tracing the modified and unmodified peptide 
fragments. 
 
2.3.3 Determination of conjugation sites in the I-domain: 
For determination of FITC conjugation sites, a classical peptide-mapping technique 
involving trypsin digestion and ESI-Q-TOF mass spectrometry followed by computer-
facilitated data analysis of peptides was performed. It is well known that trypsin cleaves 
the C-terminal Lys and Arg residues; however, the modified Lys residues in the I-domain 
cannot be clipped by trypsin.  Thus, the total ion chromatograms (TIC) from the tryptic 
digest of FTC-I-domain and parent I-domain proteins were compared (Fig. 3A-B). The 
TIC shows differences in the profiles, peak intensities, and retention times. For example, 
the increase in the retention time of the dye-modified peptides is due to the increase in 
hydrophobicity of the peptide fragment conjugate to the dye. Because of the large 
differences between the chromatograms of tryptic digests of FTC-I-domain and I-domain, 
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Figure 3. The ion chromatograms of tryptic digests of unmodified I-domain and FTC-I-domain. 
(A) The total ion chromatogram (TIC) of unmodified I-domain. (B) The TIC of FTC-I-domain. 
(C) The extracted ion chromatogram (EIC) of FTC-I-domain. The EIC was obtained by 
separating all the peaks containing the reporter ion (FITC; 389.98 Da  1.00 Da) from the TIC. 
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the identification of the conjugation sites using UV and/or fluorescence traces was 
laborious and time-consuming. Therefore, MS data were used to identify the modified 
peptides. During the analysis, the assumptions were that the modifications occurred at 
lysine residues and the expected mass of the uncleaved tryptic peptides increased by 390 
Da for FTC-modified peptides and 500 Da for RTC-modified peptides. Interestingly, MS 
data of the dye-modified proteins showed a unique peak that could be assigned to the 
mass of the free fluorescent dye molecule (reporter ion with a mass of 389.98 Da or 
500.26 Da), similar to that found in the model peptide analysis. Thus, the observed free 
dye molecule was derived from a specific peptide fragment upon cleaving the dye moiety 
(i.e., FTC or RTC) during collision-induced dissociation (CID).  
The facile release of reporter ion was fundamental for the data analysis. Considering 
this key observation, the extracted ion chromatograms (EIC) containing the reporter ion 
FITC (389.98 Da) or RITC (500.26 Da) were pulled out of the total ion current 
(chromatograms) in the LC/MS profile of the modified I-domain. A similar extraction 
was also done from unmodified protein profile (data not shown). The EIC of the FTC-
modified protein shows several peaks that appeared between 7.2 and 30.0 min (Fig. 3C), 
indicating that the amino group of the lysine side chain and/or the N-terminus of 
methionine could be modified in these peptides. Then, each new peak from the EIC of the 
FTC-I-domain in the ESI-MS spectra was processed using MaxEnt3 deconvolution 
algorithm. The processed spectra were then searched for three ions: reporter ion (FTC), 
FTC-modified peptide, and its corresponding unmodified peptide.  
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The ESI-MS spectrum of a peak eluting at 22.04 min from the tryptic-digest of FTC-I-
domain is shown in Fig. 4A. The deconvoluted spectrum shows three prominent ions 
(Fig. 4B), including m/z 389.98 Da, which corresponded to the FTC moiety, m/z 2056.69  
Da, which correlated with the unmodified peptide (151FAS…FE168K; Cal: 2057.10 Da), 
and m/z 2445.66 Da, which corresponded to the modified FTC-peptide T18-19 
(151FAS…154K…FE168K or 151FAS…161K…FE168K). The FTC-peptide T18-19 has 
modification either at 154K or 161K. In addition, the ESI-MS spectrum of another peak 
eluting at 27.97 min shows a fourth ion with m/z 2834.55 Da, which corresponds to an 
FTC-peptide with modification at both the 154K and 161K residues. However, there are 
populations of protein that were not modified at both 154K and 161K residues. This is due 
to the observation of peptides T18 (m/z 1210.42) and T19 (m/z 865.31) derived from 
complete trypsin cleavage.  
In summary, a total of 8 and 6 modification sites were identified in the FTC-I-domain 
and RTC-I-domain, respectively. Tables 1 and 2 show a complete list of modified 
peptides obtained from the FTC-I-domain and RTC-I-domain. In all the identified 
peptides, the conjugation sites were assigned to the internal lysine residue except for 
peptide T1, where the conjugation site was assigned to the primary amino group or the N-
terminus of the first amino acid residue, methionine. Interestingly, most of the 
conjugation sites found in the RTC-I-domain were similar to those found in the FTC-I-
domain.  
 
 
 
 
 
115
m/z
200 400 600 800 1000 1200 1400 1600 1800 2000 2200 2400
%
0
100
%
0
100 686.59
686.24
389.98
612.40
612.18
390.98
527.79
686.91
816.22
687.24
815.87
687.59
816.54
873.24
968.62 1029.36
2056.70
389.98
1581.39
2445.66
2410.762057.91
2461.64
A
B
FTC-I-domain
ESIMS
RT 22.04 min
812 814 816 818 820
816.22
815.87
811.24 815.24814.75
816.25
816.56
816.88
816.94
817.22
82817.57
821.819.24
MaxEnt3 processed 
FITC
T18-19+FITC
T18-19
T18-19+FITC
T18-19
Figure 4. The ESI-MS and MaxEnt3 processed spectra of the peak eluting at 22.04 min 
derived from the LC/MS analysis of the tryptic digests of FTC-I-domain. (A) The ESI-MS 
of the peak eluting at 22.04 min derived from the LC/MS analysis of the tryptic digests of 
FTC-I-domain, inset shows the spectrum of FITC modified T18-19 peptide. (B) The 
MaxEnt3 processed spectrum of peak eluting at 22.04 min derived from the ESIMS 
spectra of the tryptic digests of FTC-I-domain.
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Table 1. FITC modification sites in the FTC-I-domain detected in peptides from 
trypsin digestion 
Modified 
peptide Sequence Modified sites 
T1 1MGNVDLVFLFDGSMSLQPDEFQ23K 1M 
T2-3 24ILDFMKDVM33K 29K 
T4-5 34KLSNTSYQFAAVQFSTSY52K 34K 
T6-7 53TEFDFSDYVK63R 62K 
T18-19 151FASKPASEFVKILDTFE168K 154K, 161K 
T20-21 169LKDLFTELQ178K 170K 
T21-22 171DLFTELQK179K 178K 
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Table 2. RTC modification sites in the RTC-I-domain detected in peptides from 
trypsin digestion 
Modified 
peptide Sequence Modified sites 
T1 1MGNVDLVFLFDGSMSLQPDEFQ23K 1M 
T2-3 24ILDFMKDVM33K 29K 
T4-5 34KLSNTSYQFAAVQFSTSY52K 34K 
T15-16 131YIIGIGKHFQT142K  137K 
T18-19 151FASKPASEFVKILDTFE168K 154K, 161K 
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2.4 DISCUSSION 
 
The conjugation method adopted for the preparation of the I-domain-fluorescent dye 
conjugates yields samples with a heterogeneous distribution of fluorochrome groups 
covalently linked to the lysine residues. However, the reaction conditions have been 
optimized to maintain batch-to-batch reproducibility. Each batch consistently showed the 
same number of fluorochrome modifications per molecule of protein as determined by 
whole protein MS analysis and UV. Also, as a quality control tool, CD spectrometry 
results showed reproducibility of the spectra of modified proteins. 
The FTC-I-domain preparation contained one to seven linked FTC molecules (Fig. 2), 
while the RTC-I-domain preparation contained one to four linked RTC molecules (data 
not shown). Out of 21 modifiable residues (20 lysine + N-terminus methionine), there are 
eight sites modified by FTC and six sites modified by RTC (Tables 1 and 2). In addition, 
all of the identified sites were partially modified. There are possibly low abundant 
modification sites that cannot be detected during LC/MS analysis. The MS data analysis 
using the reporter ion can identify almost all of the modified peptides in relatively less 
time. Also, such analysis can aid in identifying low-abundance modified peptides that fall 
within the detectable range of the instrument. However, very low levels of modified 
peptides that fall below the detection range of the instrument may not be detected; as a 
result, we cannot deny the presence of more than the observed number of modification 
sites. This study shows a combination of tryptic digest and LC ESI-MS analysis is proven 
to be a powerful technique in identifying the modification sites. 
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Identification of sites of FTC- or RTC-modification of the I-domain is necessary 
because the modified I-domain serves two main purposes. The first purpose is that the 
labeling of I-domain increases the sensitivity of detection of the protein during in vitro 
binding studies. It is hoped that conjugation with the fluorescein and rhodamine does not 
alter the structure and binding site of the I-domain. Secondly, characterization of the 
modification sites provides an idea regarding the reactivity and availability of certain 
lysine residues for conjugation with drug molecules within the I-domain. Neither of these 
goals may be accomplished if the residues at the MIDAS region and the structure of I-
domain have been altered to make the molecule inactive.  
Our results indicate that FTC-moieties are found at lysine residues away from the 
MIDAS region (Fig. 5) and that the FTC-I-domain binds to ICAM-1 on Raji cells 
(Chapter 3). The binding properties of FTC-I-domain to ICAM-1 on the cell surface are 
concentration and temperature dependent. Recently, the I-domain has been conjugated to 
antigenic peptides for targeting to antigen-presenting cells (APC) for controlling T-cell 
differentiation in autoimmune diseases (Chapter 4). The antigen-I-domain conjugate can 
suppress the progress of experimental autoimmune encephalomyelitis (EAE) in the 
mouse model, a model for multiple sclerosis. Therefore, it is necessary to study the 
mechanisms of binding the I-domain protein to intercellular adhesion molecule-1 (ICAM-
1 or CD54) proteins on the surface of leukocytes. Thus, the I-domain of LFA-1 protein 
was modified with fluorochrome, and cellular binding properties were characterized 
using human leukocyte cell lines (i.e., Raji cells).  
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K178
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K34
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Figure 5. The X-ray structure of I-domain (PDB code 1ZON). The residues in green are the 
FITC modification sites and the residues in blue are the unmodified lysine modification 
sites. The modified lysine residues and the N-terminus are labeled. The protein images were 
created using Accelrys DS Visualizer 1.7. 
 
 
 
 
121
2.5 CONCLUSIONS 
The reporter ion quickly allowed identification of peaks modified with peptides in a 
complex peptide chromatogram. The observation of reporter ion and peptide represent the 
neutral loss; can be extended to ion trap instruments that lack low mass detecting 
capabilities. 
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CHAPTER 3 
Characterization of I-domain Binding Properties to Leukocytes 
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3.1 INTRODUCTION 
Intercellular adhesion molecule-1 (ICAM-1) is an Ig-like transmembrane 
glycoprotein constitutively expressed on several cell types, including leukocytes and 
dendritic cells. ICAM-1 is an attractive target for drug delivery to immune cells, since its 
expression is elevated in several autoimmune disorders.1-7 Increased ICAM-1 expression 
has been observed on T-cells isolated from synovial fluid and brain tissue of patients 
suffering from rheumatoid arthritis and multiple sclerosis, respectively.1-3, 8-9 Elevated 
ICAM-1 expression is thought to be a direct consequence of inflammatory cytokines 
released upon the infiltration of T-cells at the site of destruction. The infiltration of T-
cells progressively modifies the clinical outcome of the autoimmune diseases by 
enhancing the immunogenic response. Cell adhesion molecules (CAM), including 
ICAM-1, are internalized into the cell cytoplasmic domain via a unique pathway referred 
to as CAM-mediated endocytosis.10-13 Ligands that bind to CAM can be used to 
selectively target drugs for intracellular delivery to immune cells expressing these 
upregulated adhesion molecules. Therefore, I-domain can be utilized to target drugs to 
cells with upregulated ICAM-1 during inflammation. ICAM-1 targeting offers not only 
surface binding but also intracellular drug delivery. 
The natural counter-receptor of ICAM-1 is leukocyte function associated antigen-1 
(LFA-1, αLβ2, CD11a/CD18), a transmembrane cell surface glycoprotein.14-15 It belongs 
to the integrin superfamily of adhesion molecules, widely expressed on immune cell 
subsets. It is comprised of heterodimeric α (180kDa) and β (95kDa) subunits, which are 
non-covalently associated.16-17 The α-subunit (CD11a) of LFA-1 consists of an amino 
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terminal-inserted-domain (I-domain, approximately 200 amino acids), which is sufficient 
for LFA-1 binding to ICAM-1. The I-domain is structurally located at the top of the α-
subunit with a central five-stranded parallel β-sheet surrounded by seven α-helices; it has 
two important sites for modulation of binding to ICAM-1.17-18 The first site is a unique 
metal ion-dependent adhesion site (MIDAS). The I-domain binds to domain-1 (D1) of 
ICAM-1 through its MIDAS, which involves coordination of a divalent cation (i.e., Mg2+ 
or Ca2+) via the Asp137, Ser139, Ser141, Thr206 and Asp239 residues.19 The second 
important site is the I-domain allosteric site (IDAS); IDAS is an important binding site 
for small molecule inhibitors of ICAM-1/LFA-1-mediated cell-cell adhesion. Although 
the I-domain protein has long been studied, its potential use as a drug targeting molecule 
has not been investigated to date. Therefore, we began to investigate the utility of the I-
domain to deliver drugs and antigen peptides to immune cells for controlling autoimmune 
diseases such as multiple sclerosis, rheumatoid arthritis, and type-1 diabetes. 
In this work, we studied the binding and uptake properties of the fluorescence-labeled 
I-domain (FITC-I-domain) by ICAM-1 on Raji cells to evaluate the possible applicability 
of the I-domain to target drugs to cells with upregulated ICAM-1 for improving drug 
efficacy and lowering side effects. ICAM-1 was chosen because it can undergo 
endocytosis and cellular recycling.10-13 In this case, several of the lysine residues of the I-
domain were derivatized with fluorescein isothiocyanate (FITC) to generate FITC-I-
domain. The binding properties of FITC-I-domain to ICAM-1 on Raji cells after 
incubation at 4 °C and 37 °C were characterized by flow cytometry as well as binding 
modulation using anti-I-domain and anti-ICAM-1 antibodies. The cellular localization of 
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FITC-I-domain was determined by confocal microscope, and the amounts of the I-
domain on the cell surface and in the intracellular compartments were determined using 
fluorescence intensity integrations. Finally, the effect of divalent cations on binding 
FITC-I-domain to ICAM-1 was also determined. 
 
3.2 MATERIALS AND METHODS  
 
3.2.1 Materials  
Fluorescein isothiocyanate (FITC) isomer-I, phorbol 12-myristate-13-acetate (PMA), 
tumor necrosis factor- (TNF-) and human IgG were purchased from Sigma-Aldrich 
(St. Louis, MO). 4',6-Diamidino-2-phenylindole (DAPI) and Alexa Fluor 647 phalloidin 
were purchased from Molecular Probes (Eugene, OR). Anti-human-ICAM-1 mAb to 
domain D1 (clone 15.2), anti-human-ICAM-1 to domain D2 (clone 8.4A6), mouse IgG1 
(clone MOPC 31C), anti-human LFA-1 CD11a (clone 38), mouse IgG2a (clone RPC 5), 
and polyclonal goat anti-mouse IgG/IgM FITC were purchased from Ancell Cooperation 
(Bayport, MN). Anti-human-ICAM-1 mAb to domain D1 (clone RR1/1) was purchased 
from Millipore (Billerica, MA). 
 
3.2.2 Cell culture 
Cells were purchased from ATCC (Rockville, MD and propagated in an RPMI-1640 
medium containing 10% v/v fetal bovine serum, 100 units/mL penicillin G sodium, 100 
μg/mL streptomycin sulfate, and 2.0 g/l NaHCO3. The cells were maintained at a density 
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of 1.5 × 106 to 2 × 106/mL at 37 °C in 95% humidified and 5% CO2 atmosphere. As 
necessary, MOLT-3 cells were activated in medium containing PMA for 16 h or TNF- 
for 24 h with final concentrations of 0.2 μM and 10 ng/mL, respectively. 
 
3.2.3 Protein expression and purification 
The expression of I-domain has been described elsewhere.20  Briefly, the I-domain 
DNA sequence was subcloned into pET-11d vector followed by transformation into 
competent E. coli BL21 cells (Stratagene, La Jolla, CA).  Then, the E. coli cells were 
cultured and the induction of protein overexpression was done using isopropyl D-thio-
galactoside (IPTG, Sigma-Aldrich). For isolating the protein, the cell pellets were lysed 
in 10 mL of homogenization buffer (HB) using a French press followed by centrifugation 
(20000 × g) at 4 °C for 1 h. The majority of the I-domain was found in the protein pellet. 
After washing, the cell pellet was resuspended in 15 mL of denaturing buffer (DB, 6 M 
guanidine-HCl and 50 mM Tris, pH 8.5) and incubated for 1 h at room temperature 
before centrifugation for 30 min to remove the remaining cell debris. The supernatant 
was diluted to a protein concentration of 1 mg/mL and concentrated with Amicon 
ultrafiltration cell (Millipore) with 5,000 MWCO ultra-filtration membranes. After 
dialysis against RFB and PBS containing 10 mM MgSO4 at 4 °C, the folded I-domain 
protein was purified by passing it through a Superdex 200 size-exclusion column 
(Amersham Biosciences, Pittsburgh, PA).21 The protein was concentrated to 10 mg/mL, 
and the concentration was measured at 280 nm using an extinction coefficient of 8940 M-
1 cm-1. The purity of the I-domain was determined by SDS-PAGE gel and confirmed by 
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electrospray ionization mass spectrometry (ESI-MS) with an m/z ratio of 1881.2 
corresponding to [M + 11H]. The secondary structure of the folded protein was 
determined using far-UV circular dichroism (CD). 
 
3.2.4 Conjugation of FITC to the I-domain to give FITC-I-domain 
The conjugation of FITC to the I-domain protein was performed by following the 
method previously described.22 Briefly, one-fourth volume of 1.0 M NaHCO3/Na2CO3 
buffer pH 9.0 was added to the I-domain solution (6 mg/mL) followed by addition of a 
25-fold molar excess of freshly prepared FITC solution (5 mg/mL) in DMSO. The 
mixture was stirred in the dark for 2 h at 25 °C. At the end of the reaction, the pH was 
readjusted to 7.4 using 0.1 N HCl. Immediately the mixture was purified to separate the 
conjugated protein from free FITC using a Superdex 200 size-exclusion column. The 
fractions for the FITC-I-domain were collected and concentrated by ultrafiltration. The 
concentration of the pure conjugated protein was determined using a UV method 
described previously22 by measuring the absorbance at 280 nm and 495 nm following the 
equation: 
Concentration of I-domain protein (mg/mL) = [A280-(0.35 × A495)]/0.432 
where 0.432 is the A280 of I-domain at a concentration of 1.0 mg/mL and 0.35 × A495 is 
the correction factor due to the absorbance of FITC at 280 nm. The purity of the FITC-I-
domain conjugate was confirmed by SDS-PAGE gel, and the number of FITC molecules 
conjugated to the I-domain protein was determined by ESI-MS. The effect of conjugation 
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on the secondary structure was evaluated by comparing the CD spectrum of the I-domain 
conjugate and that of the parent I-domain. 
 
3.2.5 Flow cytometry 
3.2.5.1 Cell preparation: The cell preparation described here was carried out in the 
same manner for all the experiments described below. Cells from the stock were 
centrifuged at 500 × g for 5 min and then resuspended in sterile PBS to reach a 
concentration of 5 × 105/mL. Aliquots of 1.0 mL of the cell suspension were added to 1.5 
mL centrifuge tubes followed by centrifugation at 500 × g. The resulting supernatants 
were carefully aspirated without disturbing the cell pellets; the pellets were used for the 
following experiments. 
  
3.2.5.2 Determination of cell surface expression of ICAM-1 receptor: To decrease the 
non-specific binding, 20 µL of human IgG (300 µg/mL) in FACS buffer containing PBS 
(10 mM sodium phosphate, 150 mM sodium chloride pH 7.2-7.5, 1% BSA, and 0.05% 
sodium azide) was added to the cell pellets and incubated for 5 min at 4 °C. Then, 80 µL 
of anti-CD54 (clone 15.2) or isotype control primary antibody sub-stock ranging from 20 
to 0.0006 µg/mL dilutions in FACS buffer was added to the cells, followed by incubation 
for 45 min at 4 °C. The cells were washed twice with 0.5 mL FACS buffer and 
centrifuged at 500 × g for 5 min. Into the cell pellet, 50 µL of FITC-labeled secondary 
antibody (1:60 dilution) was added and incubated for 30 min at 4 °C, followed by 
extensive washing with FACS buffer. The cell pellet was resuspended in 300 µL 2% 
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paraformaldehyde/PBS and stored at 4 °C prior to analysis. The samples were analyzed 
using a FACScan apparatus (Becton Dickinson, Franklin Lakes, NJ) equipped with 
CELL QUEST software program. As many as 10,000 cells were counted for every 
sample during acquisition, and each experiment was done at least in triplicate. Cells 
without antibody treatment were used as controls. The control histogram was placed 
within 100 to 101 on the log scale of fluorescence intensity by adjusting the fluorescence 
detector. The binding intensities were represented as their relative values to the reference 
conditions and were determined from the mean values of the histograms for cell number 
and log fluorescence intensity (mean fluorescence intensity (MFI) corrected for non-
specific fluorescence). 
 
3.2.5.3 Concentration- and temperature-dependent binding of the FITC-I-domain 
protein: The cell pellet was resuspended in PBS containing increasing concentrations of 
FITC-I-domain protein from 0 to 52 µM at 4 °C and up to 156 µM at 37 °C and 
incubated for 60 min. At the end of the incubation period, the cells were washed three 
times with FACS buffer, and the cell suspension was centrifuged at 500 × g for 5 min. 
The cells were fixed using 2% paraformaldehyde/PBS. The resulting samples were 
analyzed using flow cytometry, and the MFI was determined as described above. 
 
3.2.5.4 The effect of anti-ICAM-1 or anti-LFA-1 mAb on FITC-I-domain binding: 
Binding of FITC-I-domain to ICAM-1 was also evaluated in the presence of anti-ICAM-
1 and anti-LFA-1 (anti-CD11a) mAb. For anti-ICAM-1 mAb, the cells were first treated 
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with 20 μl human IgG (300 μg/mL in FACS buffer) for 5 min at 37 °C followed by pre-
incubation for 30 min at 37 °C with 30 μl of anti-ICAM-1 (either clone 15.2,  RR1/1 and 
8.4A6) or isotype controls mAb with the final mAb concentration of 0.2 µM. Then, the 
cells were incubated with 50 μl of FITC-I-domain (24 µM) for another 1 h at 37 °C. The 
cell suspension was centrifuged, washed, and fixed before flow cytometry analysis. 
For anti-LFA-1 mAb blocking, 5 µM FITC-I-domain was first incubated with 
equimolar amounts of anti-LFA-1 (clone 38) mAb or its isotype control antibody in 
buffer for 30 min at 37 °C; then, this mixture was added to cells pretreated with human 
IgG and incubated for 1 h at 37 °C. The cell suspension was centrifuged, washed, and 
fixed before analysis by flow cytometry.  
 
3.2.5.5 Divalent cation-dependent binding of the FITC-I-domain protein: The cells 
were incubated for 1 h at 37 °C with FITC-I-domain protein (25 µM) in the absence and 
presence of 1.5 mM CaCl2, MgCl2, MnCl2, CaCl2/EDTA, MgCl2/EDTA, or 
MnCl2/EDTA in PBS. After incubation, the cells were treated as shown above prior to 
flow cytometry analysis. 
 
3.2.5.6 Time- and temperature-dependent binding of the FITC-I-domain protein: The 
cells were incubated with 100 µL of 25 µM FITC-I-domain prepared in FACS buffer for 
0, 5, 10, 15, 30, 60, 120, 180, and 360 min at 4 °C and 37 °C. After washing and fixing, 
the cells were subjected to flow cytometry analysis. 
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3.2.6 Confocal microscopy study 
Raji cells were centrifuged (500 × g) for 5 min and re-suspended in sterile warm PBS 
to a final concentration of 2.5 × 105/mL, and 1.0 mL aliquots were dispensed into nine 
centrifuge tubes. After centrifugation (500 × g) and removal of the supernatant solution, 
10 µL of FACS buffer was added to cells pellets, and the cell suspension was equilibrated 
for 5 min at either 4 °C or 37 °C. Then, 15 µL of FITC-I-domain (100 µM) was added to 
the cell suspension and incubated for 0, 5, 10, 15, 30, 60, 120, 180, and 360 min. At each 
time point, cells were centrifuged, washed twice (with FACS buffer), and fixed with 100 
µL of 4% paraformaldehyde in PBS. To the fixed cells, 100 µL of 16.5 nM Alexa Fluor® 
647 phalloidin for actin staining and 12.5 µL of 5 µM DAPI for nuclear staining were 
added followed by overnight incubation at 4 °C. The following day, these samples were 
mounted on a slide and imaged using a Yokugawa CSU-10 spinning disk confocal unit 
attached to an Olympus IX-81 inverted microscope platform (Olympus America, Inc., 
Center Valley, PA) Images were captured using a Hamamatsu C9100 electron multiplier 
1000 × 1000 pixel CCD camera and the SlideBook software package (Intelligent Imaging 
Innovations, Denver, CO). The resulting images were analyzed using the program 
CellProfiler23 to segment regions of interest for measuring fluorescence intensity 
associated with the membrane and the cytoplasm for each cell examined.  
 
 
 
 
 
 
 
135
3.2.7 Statistical analysis 
All the values obtained in the above experiments were expressed as mean ± SE. The 
differences between groups were tested for statistical significance using Student's t-test. 
The presence of significant difference is denoted with p-values of < 0.05 or < 0.01. 
 
3.3 RESULTS 
 
3.3.1 Fluorescein conjugation to I-domain: 
The I-domain has been successfully conjugated with fluorescein group at several of 
the 20 lysine residues to make FITC-I-domain (Scheme 1). Reproducibility of the 
conjugation was achieved by optimizing the pH, ratio of I-domain/FITC, temperature, 
and reaction time. The FITC-I-domain was easily separated from the excess FITC using 
SEC (Fig. 1A). The pure FITC-I-domain shows only a single band on SDS-PAGE when 
stained with Coomassie blue or upon shining UV light on the gel (lane 4, Fig. 1B). In 
contrast, the crude reaction product shows two spots by Coomassie blue and three 
fluorescent spots by UV light (lane 2, Fig. 1B) and the parent I-domain only shows one 
spot by Coomassie blue and no spot found by UV (lane 3, Fig. 1B).  
The ESI-MS data indicate one to seven FITC groups attached to the I-domain with the 
average of 3.5 FITC groups per I-domain molecule (top panel, Fig. 1C). There is no 
unconjugated I-domain with a MW of 20,682 found in the MS spectrum (bottom panel, 
Fig. 1C). The CD spectrum of FITC-I-domain is similar to the spectrum of unmodified I-
domain (Fig. 1D) suggesting that there is no alteration in the secondary structure of 
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Scheme 1. Reaction of I-domain protein with FITC along with the reaction 
conditions listed. 
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FITC labeled 
I-domain Protein
Free 
FITC
Figure 1A. Separation of the FITC-conjugated I-domain protein from the unreacted 
(free) FITC using size-exclusion chromatography (SEC). 
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Figure 1B. SDS-PAGE analysis of pure FITC-I-domain protein after staining with 
Coomassie blue (left) and before staining under UV light (right): molecular weight 
marker (lane 1), reaction mixture of I-domain protein and FITC (lane 2), unmodified 
I-domain protein (lane 3), and FITC-conjugated I-domain protein (lane 4). 
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Figure 1C. ESI-MS analysis of the FITC-I-domain protein (top) and the I-domain 
protein (bottom).
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Figure 1D. CD spectra of unmodified I-domain protein (red), FITC conjugated   
I-domain protein (green). 
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FITC-I-domain. The predicted secondary structure of FITC-I-domain from CD spectra 
shows 37% α-helix and 26% β-sheet, which are similar to the secondary structure content 
from X-ray crystallography (i.e., 37% α-helix and 22% β-sheet).24 
 
3.3.2 Comparison of ICAM-1 expression on Raji, HL-60, and Molt-3 cells: 
The ICAM-1 expressions on HL-60, Molt-3 T-cells and Raji cells were determined 
using anti-ICAM-1 D1 (clone 15.2) mAb to select the appropriate cells for FITC-I-
domain binding studies (Fig. 2). In all three cell lines, the anti-ICAM-1 mAb binding 
increased upon an increase in concentration, and the binding eventually saturated at 
higher concentrations. The highest ICAM-1 level was found in Raji cells followed by 
Molt-3 cells and HL-60 cells. As a negative control, the isotype mAb did not show any 
appreciable binding to all three cells. Upon induction with TNF-α or PMA, the 
expression of ICAM-1 was slightly increased in Molt-3; however, the increase in ICAM-
1 expression did not match the amount of ICAM-1 on the un-activated Raji cells. Based 
on these results, the Raji cells were used to perform binding experiments using FITC-I-
domain protein.  
 
3.3.3 FITC-I-domain binding to ICAM-1 on Raji Cells:  
At 4 °C, the FITC-I-domain exhibited an increase in binding with saturation around 30 
µM of added protein (Fig. 3A). At 37 °C, there was no observable saturation even up to 
threefold higher concentration (0–156 µM, Fig. 3B). At 37 °C, the results suggest that 
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Figure 2. Comparison of the surface expression of ICAM-1 receptors in different cell 
lines using anti-ICAM-1 (CD54) mAb 15.2. Data shown from one representative 
experiment ± S.E. (n = 3) for Raji cells and (n = 1) for Molt-3 and HL-60.
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Figure 3. Binding of FITC-I-domain to ICAM-1-expressing Raji cells at 
4 °C (A) and 37 °C (B). The results are expressed as the mean ± S.E. (n = 
3).
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there is binding as well as receptor-mediated uptake of FITC-I-domain. Confocal 
microscopy was used to study the uptake properties of the conjugate. 
 
3.3.4 The effect of anti-ICAM-1 and anti-LFA-1 mAb on FITC-I-domain binding:  
The effect of anti-LFA-1 (anti-CD11a, clone 38) and anti-ICAM-1 mAb on binding 
of FITC-I-domain to ICAM-1 was determined to access its ICAM-1 specificity. Anti-
CD11a mAb binds to I-domain of LFA-1. It blocked 55% of FITC-I-domain binding to 
Raji cells; in contrast, the isotype control mAb did not block the FITC-I-domain binding 
(Fig. 4A). The result from this experiment is consistent with previous results by others 
using cell based assay25 and solid phase ELISA assay.26 
Instead of blocking, all three anti-ICAM-1 mAb (clone RR1/1, 15.2, and 8.4A6)   
enhanced binding (164%, 146%, and 179%, respectively) of FITC-I-domain to ICAM-1 
on Raji cells (Fig. 4B) compared to the isotype control mAb. For RR1/1 mAb, the 
obtained results were unexpected because this mAb recognizes the Gln-73 residue of 
domain-1 of ICAM-127 and it an effective blocker of ICAM-1/LFA-1-mediated cell-cell 
adhesion.28 Anti-ICAM-1 clones 15.2 and 8.4A6 that recognize domain-1 and -2 of 
ICAM-1, respectively, are also inhibitors of ICAM-1 binding to LFA-1.  
 
3.3.5 Ca2+ enhances binding of FITC-I-domain to ICAM-1:  
The active state of I-domain interacts with Glu-34 of ICAM-1 via its MIDAS region 
through a coordination of a divalent metal ion. Thus, the effect of various divalent cations 
on binding affinity of FITC-I-domain to ICAM-1 on Raji cells was evaluated. Ca2+ 
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Figure 4. Effect of function blocking mAb [A. anti-LFA-1 (CD11a) I-domain mAb and B.
anti-ICAM-1 (CD54) mAb] on the binding of FITC-I-domain protein to the ICAM-1 
receptor expressed on the surface of Raji cells. The results are expressed as the mean ± S.E. 
(n = 3). There are significant differences in the binding of FITC-I-domain protein; control 
vs. mAb 38 (*p<0.01), RR1/1 (*p<0.05), 15.2 (*p<0.05), and 8.4A6 (*p<0.05).
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significantly enhances binding of FITC-I-domain to the cells compared to Mg2+ or Mn2+ 
and no divalent cations (Fig. 5). The increase in FITC-I-domain binding could be 
reversed to normal using Ca2+ and EDTA, suggesting the involvement of Ca2+ in the 
MIDAS region of FITC-I-domain during binding to ICAM-1. Finally, the presence of 
EDTA in Mg2+- or Mn2+-containing media shows binding of FITC-I-domain similar to 
that of control (absence of cations). These results indicate that Ca2+ is a better 
coordination cation than Mg2+ or Mn2+ for FITC-I-domain binding to ICAM-1. 
 
3.3.6 FITC-I-domain uptake by Raji cells:  
The results of concentration-dependent binding studies suggest that FITC-I-domain 
binds to the cell surface only at 4 °C; however, a combination of binding and uptake of 
FITC-I-domain is observed at 37 °C (Fig. 3). To determine the uptake properties, time- 
dependent binding at 4 °C and 37 °C was studied by flow cytometry (Fig. 6). At 37 °C, 
64% of binding was observed within 5 min; 100% binding was arbitrarily assigned to 
fluorescence intensity at the 360-min time point with a plateau starting at the 30-min 
point. A three-fold decrease in the fluorescence intensity was found upon 4 °C incubation 
of the protein, suggesting that the difference in fluorescence intensities at 37 and 4 °C 
was due to protein uptake. 
To visualize the binding and uptake, Raji cells were incubated with FITC-I-domain at 
either 4 °C or 37 °C with increasing incubation time up to 360 min. This was followed by 
capturing a confocal Z-section series over a depth of 12-microns. The green fluorescence 
from the protein could be clearly identified in the cells treated at 37 °C (Figure 7A) as 
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Figure 5. Effect of divalent cations on FITC-I-domain binding to ICAM-1 
receptors expressed on the surface of Raji cells. The results are expressed as the 
mean ± S.E. (n = 3). There are significant differences in the binding of the 
FITC-I-domain protein; control vs. CaCl2 (*p<0.05).
C
on
tr
ol
C
aC
l 2
M
gC
l 2
M
nC
l 2
C
aC
l 2 
+ 
E
D
TA
M
gC
l 2 
+ 
E
D
TA
M
nC
l 2 
+ 
E
D
TA
0
25
50
75
100
125
150
175
200
FI
TC
 I-
do
m
ai
n 
bi
nd
in
g 
(%
 C
on
tr
ol
)
*
 
 
 
148
 
025507510
0
12
5
0 
m
in
5 
m
in
10
 m
in
15
 m
in
30
 m
in
60
 m
in
90
 m
in
12
0 
m
in
18
0 
m
in
36
0 
m
in
FITC-I-domain binding
Mean Fluorescence Intensity (MFI)
4 
ºC
37
 ºC
Fi
gu
re
 6
.
FI
TC
-I
-d
om
ai
n 
pr
ot
ei
n 
bi
nd
in
g 
to
 R
aj
i c
el
ls 
at
 3
7 
°C
 (c
lo
se
d 
ba
rs
) a
nd
 4
 °C
 (o
pe
n 
ba
rs
) a
s a
 fu
nc
tio
n 
of
 ti
m
e.
 T
he
 v
al
ue
s f
or
 th
e 
m
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
 w
er
e 
ob
ta
in
ed
 u
si
ng
 fl
ow
 c
yt
om
et
ry
. T
he
 re
su
lts
 a
re
 
ex
pr
es
se
d 
as
 th
e 
m
ea
n 
±
S.
E.
 (n
 =
 3
).
 
 
 
 
149
Figure 7A. Confocal microscopy images of FITC-I-domain binding to ICAM-1 on 
the surface of Raji cells at 37 °C with increasing incubation time (0, 5, 10, 15, 30, 
60, 120, 180, and 360 min). Raji cells stained with DAPI (blue) for the nucleus, 
Alexa Fluor® 647 Phalloidin (red) for actin, and FITC-I-domain (green). Phase 
contrast image (first row), DAPI (second row), FITC-I-domain (third row), Alexa
Fluor® 647 Phalloidin (fourth row), and merged image of all the three colors (fifth 
row).
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early as the 5-min time point. In contrast, only limited green fluorescence was found 
associated with the cells incubated with the protein at 4 °C (Figure 7B).  
To differentiate surface binding and intracellular uptake of FITC-I-domain, the cell 
nucleus and actin were stained with DAPI and Alexa Fluor® 647 phalloidin, respectively. 
Using the CellProfiler cell image analysis software, captured images were segmented and 
processed for green fluorescence from FITC-I-domain associated with regions defined as 
either the whole cell (i.e., region of DAPI staining plus the region of Phalloidin-Alexa 
Fluor® 647 staining) or the cytoplasm (i.e., regions of Phalloidin-Alexa Fluor® 647 
staining) alone. The average integrated fluorescence intensity (AIF) values associated 
with the whole cell upon protein incubation at 37 °C were increased upon longer 
incubation time compared to those incubated at 4 °C; these results were consistent with 
data from flow cytometry (Fig. 8A). Similarly, the AIF values associated with the 
cyctoplasm were higher at 37 °C than at 4 °C (Fig. 8B). The AIF intensity values 
associated with the membrane also increased with incubation time at 37 °C (Fig. 8C). 
These results indicate that FITC-I-domain conjugate binds and internalizes in B-cells at 
37 °C.  
 
3.4 DISCUSSION 
This study is the first to show that I-domain can enter the intracellular space of Raji cells 
via a receptor-mediated endocytosis process. Previously, cLABL peptide derived from 
the sequence of I-domain was found in the intracellular space of T-cells upon binding and 
ICAM-1-mediated endocytosis.29 Nanoparticles decorated with cLABL 
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Figure 7B. Confocal microscopy images of FITC-I-domain binding to ICAM-1 on 
the surface of Raji cells at 4 °C with increasing incubation time (0, 5, 10, 15, 30, 
60, 120, 180, and 360 min). Raji cells stained with DAPI (blue) for the nucleus, 
Alexa Fluor® 647 Phalloidin (red) for actin, and FITC-I-domain (green). Phase 
contrast image (first row), DAPI (second row), FITC-I-domain (third row), Alexa
Fluor® 647 Phalloidin (fourth row), and merged image of all the three colors (fifth 
row).
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peptide or anti-ICAM-1 antibody were also endocytosed into cellular compartments (i.e., 
endosomes) upon binding to ICAM-1 on the cell surface.13, 30-31 Anti-ICAM-1-coated 
nanoparticles successfully delivered lysosomal enzyme in to cells obtained from patients 
suffering from lysosomal storage disorder.32 These nanoparticles are endocytosed via a 
non-classical mechanism upon ICAM-1 clustering, which is called CAM-mediated 
endocytosis. The CAM-mediated endocytosis is distinct from classical clathrin- or 
caveolar-mediated internalization as well as from phagocytosis and micropinocytosis 
processes.13, 33 
ICAM-1 has important roles in different pathological conditions such as autoimmune 
diseases,34-35 cancer,34, 36 and atherosclerosis.37 In multiple myeloma, lung, and pancreatic 
cancer cells, the level of ICAM-1 expression is increased.34 Upregulation of ICAM-1 is 
also found on the endothelium during inflammation, which is influenced by cytokines 
(i.e., TNF-, IL-1 and IFN-), and this upregulation induces adhesion of leukocytes prior 
to subsequent trans-endothelial migration to the injured tissue.38 Cell surface ICAM-1 
molecules serve as endocytosis receptors for human rhinovirus (HRV) and respiratory 
syncytial virus.39-40 Thus, the I-domain can be explored as a carrier to target drugs to 
leukocytes, cancer cells, and inflammatory endothelial cells with up-regulated ICAM-1 
receptors. The hope is that the I-domain-drug conjugate can direct the drug molecule to 
the target pathogenic cells while at the same time avoiding normal cells to minimize the 
toxic side-effects of the drug. The small drugs can be conjugated to several of the 20 Lys 
residues of the I-domain. Here, several of these Lys residues of the I-domain were 
conjugated with FITC groups and still maintained the I-domain conformation (Fig. 1C), 
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ICAM-1-binding (Fig. 3), and uptake properties (Figs. 6–8). We have determined using 
tryptic mapping, mass spectrometry, and molecular modeling that the FITC-conjugated 
Lys residues are away from the binding site of I-domain to ICAM-1. 
It is clear that FITC-I-domain binds to ICAM-1 on Raji cells and that this binding can 
be inhibited by anti-LFA-1 mAb to I-domain clone 38, suggesting that the antibody 
blocks the I-domain binding site to ICAM-1 (Fig. 4). However, all anti-ICAM-1 mAb 
enhance the binding of FITC-I-domain (Fig 4), indicating that the I-domain has a 
different binding site on ICAM-1 than does these mAb. A similar effect of RR1/1 mAb 
was observed in the binding of a GST-tagged I-domain (I-GST) to a surface-coated 
ICAM-1Fc using a solid-phase ELISA assay. This result also suggests that the I-domain 
protein interacts with Glu-34 of ICAM-1 but not Gln-73.26 There are several possible 
explanations for the enhancement of I-domain binding. First, anti-ICAM-1 mAb binding 
may induce conformational change in a single ICAM-1 to an active conformation for 
binding to the I-domain. Second, anti-ICAM-I mAb could promote dimerization or 
oligomerization (clustering) of the ICAM-1 on the cell surface that binds to multiple 
regions of a single I-domain molecule. Finally, the mAb can induce ICAM-1 
conformational change to promote dimers or cluster for binding to multiple sites in an I-
domain molecule to increase the binding affinity. The antibody studies indicate that 
FITC-I-domain binds to ICAM-1 on Raji cells, and the presence of FITC labels does not 
alter its binding to ICAM-1. 
The binding of FITC-I-domain to ICAM-1 is enhanced by Ca2+ ion but not Mg2+ or 
Mn2+ ions (Fig. 5); this increase in binding can be reversed upon addition of EDTA. It is 
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interesting to that only Ca2+ ion enhances the binding of FITC-I-domain to ICAM-1; this 
could be due to the fact that Ca2+ has the appropriate size and electrostatic interaction 
compared to Mg2+ and Mn2+ to coordinate with the MIDAS region of the I-domain and 
the Glu-34 residue of ICAM-1. Mn2+ strongly augmented the binding of LFA-1 
expressed on the surface of T-cells to its ligand, ICAM-1,41 suggesting that Mn2+ is able 
to induce conformational changes in LFA-1 favoring the high affinity state. Binding of 
Mg2+ with in the I-domain also results in a conformational change such that the C-
terminal 7 helix swings away from the central -sheet, resulting in a high affinity form 
of I-domain.42 
Receptor-mediated internalization, along with other technological advances in drug 
conjugation, may be a useful application for I-domain in targeting drugs to inflammatory 
diseases, autoimmune diseases, and cancer. Recently, we have successfully conjugated an 
antigenic peptide with an I-domain protein via a linker. The antigenic peptide-I-domain 
conjugate effectively suppressed experimental autoimmune encephalomyelitis (EAE) in 
female SJL/J mice as a model for human multiple sclerosis (Chapter 4). 
We believe that FITC-I-domain binding to ICAM-1 on the cell surface induces 
ICAM-1 clustering, further initiating the internalization of the conjugate via an ATP-
dependent process. We speculate that this is CAM-mediated endocytosis. The binding 
sites on ICAM-1 for HRV and LFA-1 are distinct with partial overlaps in the binding 
residues. Studies done using ICAM-1 mutants revealed that the binding site for HRV on 
ICAM-1 is Gln 58, while for LFA-1 is Glu 34.27 Antibodies can selectively bind to the 
target receptor, but it is not guaranteed that such interactions necessarily result in 
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endocytosis. In vitro and in vivo animal studies done using anti-ICAM-1 have shown that 
the ICAM antibody internalizes poorly.43 In contrast, targeting using LFA-1 I-domain-
conjugates is mediated by the comparatively natural interaction between the I-domain 
and its ligand ICAM-1 receptor. Therefore, I-domain conjugates may offer an alternate 
solution for selective and effective internalization.  
ICAM-1 targeting offers a variety of applications. ICAM-1-targeted isotopes were 
used for detection of lung inflammation at a very early stage.44 Liposomes conjugated 
with anti-ICAM-1 were able to bind to epithelial and endothelial cells in a dose- and 
time-dependent manner.45 Murciano et al. demonstrated the delivery of an anti-ICAM-1 
conjugated tissue-type plasminogen activator (tPA) to endothelial cells in vitro and in an 
in vivo animal model43 Thus, ICAM-1 targeting has been utilized for imaging, diagnosis, 
and delivery of therapeutic agents.  
 
3.5 CONCLUSIONS 
In this chapter, we have shown that the FITC-I-domain can bind to ICAM-1 on the 
surface of B-cells. The conjugate binding is influenced by the presence of calcium. 
Further, the conjugate is internalized by ICAM-1 on B-cells, probably via receptor-
mediated endocytosis, suggesting that the I-domain can be used to target drugs to the 
cytoplasmic compartment of cells expressing ICAM-1. In the future, the utility of I-
domain proteins in delivering anti-inflammatory, anti-cancer, and antigenic peptides will 
be investigated.  
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CHAPTER 4 
In vivo Suppression of EAE by PLP-I-domain Conjugates 
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4.1 INTRODUCTION 
Autoimmune diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), and 
type 1 diabetes (T1D) are caused by host immune systems that recognize self tissues or 
organs. In the case of MS, the immune systems attack the myelin sheath of the neurons 
causing disruption of the signal translation in the central nervous system (CNS). One of 
the potential ways that T cells recognize the myelin sheath is by activation of a subset of 
autoreactive T cells to recognize the self myelin sheath. One possible mechanism of 
activation of a subpopulation T cell is via formation of the “immunological synapse” at 
the interface between T cells and antigen-presenting cells (APC). The immunological 
synapse is a “bull’s eye”-like structure that is composed of a cluster of interactions 
between T cell receptors (TCR) and major histocompatibility complex-peptide (MHC-p) 
at the center (Signal-1) and a cluster of interactions between costimulatory molecules (i.e. 
Signal-2, B7/CD28, ICAM-1/LFA-1) at the periphery of the bull’s eye. The 
differentiation of naïve T cells to a specific subset (i.e. TH1, TH2) is strongly dependent 
on the type of co-stimulatory signal being delivered. Blocking Signal-2 during this 
process leads to immune unresponsiveness of T cells called anergy.1 Inhibition of ICAM-
1/LFA-1 interaction suppresses TH1-type immune response and promotes a non-
inflammatory TH2-type response.2  Potential drugs such as monoclonal antibodies (mAb) 
or small molecules have been developed based on blocking Signal-2.  Drugs for 
autoimmune diseases that inhibit Signal-2 may also suppress the general immune 
response of the host; unfortunately, as a potential side effect, these drugs may 
compromise the ability of the host to respond to pathogenic infections.  
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To overcome the general suppression of immune systems, our approach is to 
modulate the activation of a subpopulation of T cells that recognizes a specific antigen 
using a bifunctional peptide inhibitor (BPI). The BPI molecules are composed of an 
antigenic peptide for the specific disease conjugated to a cell adhesion peptide via a 
spacer.3-7 GAD-BPI, PLP-BPI, and CII-BPI molecules have been shown to induce 
immunotolerance in non-obese diabetes (NOD),5 experimental allergic encephalomyelitis 
(EAE),3-4, 6-7 and collagen-induced arthritis (CIA), respectively. The antigenic peptide is 
derived from the sequence of antigenic epitope responsible for the autoimmune disease 
while the adhesion peptide is derived from either the sequence of LFA-1 (LABL) or 
ICAM-1 (cIBR7). The potential mechanism of action of BPI molecules is via 
simultaneous binding to MHC-II and ICAM-1 receptors on the surface of APC, 
respectively. Simultaneous binding to these two target receptor prevents the translocation 
Signal-1 and Signal-2 molecular complexes and inhibits the formation of the 
immunological synapse. As a result, the BPI molecules suppress the generation of 
inflammatory T cells and possibly stimulate the formation of suppressor or regulatory T 
cells.  
In this work, we have designed PLP-I-domain-1 and -2 molecules as potential 
therapeutic agents for the treatment of multiple sclerosis. PLP-I-domain was made by 
conjugating PLP139-151 peptide via a maleimide spacer to several lysine residues on the I-
domain protein derived from the α-subunit of LFA-1. The I-domain is the binding region 
of LFA-1 to ICAM-1, and it has been shown to interact with the D1 domain of ICAM-1.8 
Compared to the cell adhesion peptide LABL, I-domain offers a unique divalent cation 
 
 
 
167
coordination site called metal ion-dependent adhesion site or MIDAS that interacts with 
the ICAM-1 D1 domain. Furthermore, there are potential multiple conjugation sites on 
the I-domain. In this study, PLP-Cys-OH and PLP-Cys-NH2 were conjugated to -
maleimidobutyryloxy-I-domain (GMB-I-domain) at pH 8.5 and 6.6 to give PLP-I-
domain-1 and PLP-I-domain-2, respectively. The efficacies of PLP-I-domain-1 and -2 
were compared to those of PBS, I-domain, GMB-I-domain as negative controls, and Ac-
PLP-LABL-NH2 and Ac-PLP-cIBR7-NH2 as positive controls. The results show that the 
difference in in vivo activity of PLP-I-domain-1 and PLP-I-domain-2 was due to the 
conjugation sites of the two PLP-I-domain molecules. 
 
 
4.2 MATERIALS AND METHODS  
 
4.2.1 Materials 
The amino acids used for peptide synthesis were purchased from Peptide 
International (Louisville, KY). GMBS (N-[-maleimidobutyryloxy]succinimide ester) 
was from Pierce (Rockford, IL). Sequence-grade modified trypsin was from Promega 
(Madison, WI). All other chemicals or solvents were of analytical grade or better.  
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4.2.2 Mice 
The in vivo studies were carried out using female inbred SJL/J (H-2S) mice purchased 
from Charles River Laboratories, Inc. (Wilmington, MA). The animals were housed 
under specific pathogen-free conditions at an American Association for Accreditation of 
Laboratory Animal Care (AAALAC)-approved animal facility at the University of 
Kansas. All protocols involving live mice were pre-approved by the university’s 
Institutional Animal Care and Use Committee (IACUC) and are in compliance with the 
committee’s recommendations. 
 
4.2.3 Peptide synthesis 
The sequences of peptides used in the present study are listed in Table 1. The peptides 
were synthesized by standard Fmoc solid-phase peptide chemistry on appropriate PEG-
PS resin (Applied Biosystems, Foster City, CA) using the automated peptide synthesis 
system (Pioneer perspective Biosystems, Framingham, MA). Peptide synthesis and 
purification was conducted according to our previously published method.4 All peptides 
were purified using semi-preparative C18 reversed-phase HPLC, and the fractions from 
the preparative HPLC were analyzed by analytical HPLC. The pure fractions of the 
peptide were pooled and lyophilized; the molecular weight of the peptides was confirmed 
by electrospray ionization mass spectrometry (M+1) (MW PLP-Cys-OH = 1624.86; MW 
PLP-Cys-NH2 = 1623.81; MW Ac-PLP-BPI-NH2 = 3416.95; MW Ac-PLP-cIBR-NH2 = 
3093.79). 
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Table 1. List of peptides and proteins used in the present study 
Peptide/Protein Sequence 
Ac-PLP-LABL-NH2  
Ac-HSLGKWLGHPDKF-(AcpGAcpGAcp)2-ITDGEATDSG-
NH2  
Ac-PLP-cIBR7-NH2  
Ac-HSLGKWLGHPDKF-(AcpGAcpGAcp)2-
cyclo(1,8)CPRGGSVC-NH2  
PLP-I-domain-1  (HSLGKWLGHPDKFC)n-linker-I-domain    
PLP-I-domain -2  (HSLGKWLGHPDKFC-NH2)n-linker-I-domain 
GMB-I-domain [N-(-maleimido)-1-oxybutyl]n-I-domain  
I-domain 
MGNVDLVFLFDGSMSLQPDEFQKILDFMKDVMKKLSN
TSYQFAAVQFSTSYKTEFDFSDYVKRKDPDALLKHVK
HMLLLTNTFGAINYVATEVFREELGARPDATKVLIIITD
GEATDSGNIDAAKDIIRYIIGIGKHFQTKESQETLHKFAS
KPASEFVKILDTFEKLKDLFTELQKKIY 
Ac = Acetyl and Acp = Aminocaproic acid 
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4.2.4 Preparation of I-domain 
The LFA-1 I-domain protein was over-expressed, refolded, and purified as previously 
described.9 The protein purity, identity, and secondary structure were confirmed by SDS-
PAGE, mass spectrometry, and far-UV circular dichroism (CD), respectively.   
 
4.2.5 Synthesis of PLP-I-domain-1 and -2 
Two steps are required to prepare the PLP-I-domain conjugates. The first is to modify 
the amino groups of the N-terminal and side-chain of lysine residues of I-domain by 
reacting them with N-[-maleimidobutyryloxy]succinimide ester (GMBS). This step 
introduces maleimido groups on the I-domain to generate the GMB-I-domain. The 
second step is to conjugate the thiol group on the Cys residue of PLP-Cys-OH and PLP-
Cys-NH2 peptides to the maleimide groups on the I-domain to give PLP-I-domain-1 and 
PLP-I-domain-2, respectively. 
4.2.5.1 Step 1: To a total of 20 mg of I-domain solution, a tenfold molar excess of 
freshly prepared GMBS (2.71 mg) solution in DMSO (0.5 mL) was added dropwise 
followed by stirring of the mixture for 1 h at 24 °C. Then, the reaction mixture was 
subjected to purification through a Superdex 75 column to isolate the GMB-I-domain. 
The desired GMB-I-domain and the excess GMBS were eluted with PBS containing 10 
mM MgSO4. The fractions containing the GMB-I-domain were collected and 
concentrated by ultrafiltration. Modification on the I-domain using this method gave 3–
10 maleimido groups per I-domain as determined by electrospray ionization mass 
spectrometry (ESI-MS). 
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4.2.5.2 Step 2: The conjugation reactions of PLP-Cys-OH and PLP-Cys-NH2 peptides 
to GMB-I-domain were carried out at pH 8.5 and 6.6, respectively, to produce PLP-I-
domain-1 and PLP-I-domain-2. To a solution containing 10 mg of GMB-I-domain, a 15 
molar excess of PLP-Cys-OH or PLP-Cys-NH2 dissolved in PBS was added dropwise. 
During the addition of the peptide, the pH was constantly monitored and adjusted to 
either 8.5 or 6.6, depending on the reaction. During the reaction, the final concentration 
of the protein in both batches was 2.0 mg/mL. The reaction was carried out for 1 h at 24 
°C with constant stirring. After the reaction was complete, the pH of the mixture was 
readjusted to 7.4. The resulting PLP-I-domain-1 or PLP-I-domain-2 was purified using a 
Superdex 75 column. The fractions belonging to the PLP-I-domain-1 or -2 were collected 
and concentrated by ultrafiltration. Both PLP-I-domain-1 and -2 contained 0 to 5 peptide 
molecules per I-domain molecule as determined by ESI-MS. The purity of the PLP-I-
domain-1 and -2 was confirmed by SDS-PAGE gel and size-exclusion chromatography. 
The CD spectra of the PLP-I-domain-1 and -2 were compared with that of the parent I-
domain protein.  
 
4.2.6 Gel electrophoresis 
100 μg of pure protein solution of PLP-I-domain-1, PLP-I-domain-2, or I-domain 
obtained after SEC separation was mixed with a 4X Tris–glycine SDS sample buffer 
containing no reducing agent and loaded into 1.5-mm-thick 10-well NuPAGE Novex 4–
12% Bis-Tris gradient gels. After running gel electrophoresis at 150 V for 70 min, the 
gels were stained with 0.25% Coomassie blue R250 solution (10% acetic acid/50% 
 
 
 
172
ethanol/40% water) for 30 min followed by destaining (10% acetic acid/25% 
ethanol/65% water) until the bands were visible and the background was clear. 
 
4.2.7 In-Gel trypsin digestion 
A standard in-gel protein digestion protocol was followed as described elsewhere.10 
Briefly, protein bands were excised from the gel and were digested with trypsin at an 
enzyme-to-substrate ratio of 1:25 (w/w) at 37 °C overnight. To stop the digestion, 2 μL of 
glacial acetic acid was added to each sample.  
 
4.2.8 LC-MS/MS analysis of tryptic-digest products 
The products of tryptic digest from I-domain, PLP-I-domain-1, and PLP-I-domain-2 
were introduced into a capillary reversed-phase LC-MS/MS using a tandem LTQ-FT 
mass spectrometer (ThermoFinnigan, Bremen, Germany) under conditions described 
previously.11  The experimental raw data were processed using Bioworks software 
(Thermo, version 2.0) to create an MS/MS peak list in a DTA format.  Protein sequence 
mapping was performed using Sequest, Mascot (Matrix Science, version 2.2) and 
X!Tandem (www.thegpm.org) algorithms with a fragment ion mass tolerance of 0.20 Da 
and a parent ion tolerance of 1.2 Da.  Amino groups of lysine residues and protein N-
terminus were considered to be modified with maleimide linker moiety + dipeptide (Phe-
Cys). The chemical composition of the modification for PLP-I-domain-1 is C20H23N3O6S, 
delta monoisotopic mass 433.1308 and its maleimide hydrolysis product is C20H25N3O7S, 
delta monoisotopic mass 451.1413. The chemical composition of the modification for 
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PLP-I-domain-2 is C20H24N4O5S, delta monoisotopic mass 432.1467 and its maleimide 
hydrolysis product is C20H26N4O6S, delta monoisotopic mass 450.1572. The assumption 
is that the trypsin digestion cleaves at the carboxyl side of the lysine residue (12K) of the 
peptide PLP-Cys-OH or PLP-Cys-NH2. Scaffold software (Proteome Software Inc., 
version 2.06) was used to combine and validate MS/MS-based peptide identifications.  
Peptide identifications with greater than 50% probability as specified by the Peptide 
Prophet algorithm12 were accepted for reporting protein coverage.  
 
4.2.9 Induction and suppression of EAE 
Female inbred SJL/J mice, 5-7 weeks old, were randomly divided into seven groups. 
All mice were immunized with PLP139–151 in CFA to induce EAE, as reported 
previously.3-4 The PLP/CFA emulsion (50 μL per site) was administered to four separate 
regions above the shoulder and on the flanks. In addition, 200 ng of pertussis toxin (List 
Biological Laboratories Inc., Campbell, CA) was injected intraperitoneally on day 0 and 
2. Then, the mice received intravenous injections of either vehicle (PBS), PLP-I-domain-
1 (26 nmol/injection), PLP-I-domain-2 (26 nmol/injection), GMB-I-domain (26 
nmol/injection), I-domain (26 nmol/injection), or Ac-PLP-cIBR7-NH2 (52 
nmol/injection) on days 4 and 7. The Ac-PLP-LABL-NH2-treated mice received 
100nmol/injection on days 4, 7, and 10. The animals were weighed and observed daily. 
Disease progression was evaluated observed using a blinded method as reported 
previously.3-4  The clinical scores were rated using the following scale: 0–no clinical 
signs of disease; 1–tail weakness or limp tail; 2–paraparesis (weakness or incomplete 
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paralysis of one or two hind limbs); 3–paraplegia (complete paralysis of two hind limbs); 
4–paraplegia with forelimb weakness or paralysis; and 5–moribund or dead. Mice were 
euthanized once they were found to be moribund. 
 
4.2.10 Statistical analysis 
Statistical differences among the groups in clinical disease scores were determined by 
calculating the average score for each mouse from the day of disease onset to day 20 by 
One-way Analysis of Variance followed by Fisher’s least significant difference using 
StatView (SAS Institute, Cary, NC). Statistical differences among the groups in body 
weight were also analyzed in the same way. The presence of significant difference is 
denoted with p-values of < 0.05 or < 0.001. 
 
4.3 RESULTS 
 
4.3.1 Synthesis and characterization of PLP-I-domain: 
PLP-I-domain-1 and -2 were prepared by conjugating the PLP-Cys-OH and PLP-Cys-
NH2 peptides to the N-terminus and side chain amino groups of the lysine residues in the 
I-domain (Fig. 1). Thus, the amino groups in the I-domain were reacted with the active 
N-hydroxysuccinimide (NHS) ester of GMBS to produce GMB-I-domain protein via a 
stable amide bond (Step 1, Fig.1). The GMB-I-domain from the reaction mixture was 
purified from the excess GMBS using SEC (Fig. 2A). Comparison of CD spectra of 
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Figure 1. Schematic representation of two-step modification and conjugation 
reactions to prepare PLP-I-domain-1 and -2.
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Unreacted 
GMBS
GMB-I-domain
Figure 2A. SEC chromatogram showing the separation between GMB-I-domain and 
the remaining free GMBS. 
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GMB-I-domain and I-domain shows that they have similar spectra (Fig. 2B), indicating 
that adding of GMB groups does not alter the secondary structure of the GMB-I-domain.  
The composition of pure GMB-I-domain was analyzed by liquid chromatography 
coupled online with ESI-MS. The deconvoluted MS spectrum shows three to nine GMB 
groups attached to the I-domain with following masses: 21,178 Da, 21,343 Da, 21,508 
Da, 21,674 Da, 21,839 Da, 22,004 Da, and 22,169 Da (top panel, Fig. 2C). The sequential 
differences in mass are 165 Da, which is consistent for a sequential addition of GMB 
group. The first peak at 21,178 Da corresponds to the I-domain molecular weight 
conjugated to three GMB groups; therefore, the remaining peaks correspond to the I-
domain with four to nine covalently linked GMB groups, respectively. The parent I-
domain with a MW of 20,682 was not found in the MS spectrum (bottom panel, Fig. 2C).  
Along with the desired GMB-I-domain peak, there are corresponding peaks with a 
mass increase of 18 Da found in the MS spectra (top panel, Fig. 2C). These peaks 
correspond to the hydrolysis of maleimide groups or maleic acid derivatives, which are 
attached to the I-domain.13 The MS data correlate with the SDS-PAGE image of the 
isolated product of GMB-I-domain from SEC, which shows two bands on lane 4 in 
Figure 2D. These two bands are from the desired maleimide and maleic acid derivatives 
of I-domain with different electrophoretic mobility. Before purification, the reaction 
mixture (lane 3, Fig. 2D) shows three bands while the control I-domain (lane 2, Fig. 2D) 
produces only one band. The formation of maleimide hydrolysis products is increased 
upon storage; thus, it is important that the GMB-I-domain be used within 48 h after SEC 
purification. 
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Figure 2B. CD spectra of the parent I-domain (red) and GMB-I-domain (black).
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Figure 2C. Deconvoluted mass spectra of LC ESI-MS analysis of the GMB-I-domain 
protein (top) and the parent I-domain protein (bottom).  
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Figure 2D. SDS-PAGE analysis of pure GMB-I-domain protein after staining with 
Coomassie blue: molecular weight marker (lane1), the I-domain protein (lane 2), 
the reaction mixture of I-domain protein and GMBS (lane 3), and GMB-I-domain 
protein (lane 4).
1       2        3        4
GMB-I-domain after 
purification
20 kDa
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4.3.2 Conjugation of PLP-Cys-OH and PLP-Cys-NH2 peptide to GMB-I-domain: 
PLP-Cys-OH and PLP-Cys-NH2 are peptides that contain PLP139-151 sequence with an 
additional cysteine amino acid at the C-terminus. PLP-Cys-OH has open carboxylic acid 
(Cys-OH) and PLP-Cys-NH2 has amidated carboxylic acid (Cys-NH2) at the C-terminus. 
PLP-Cys-OH and PLP-Cys-NH2 peptides were reacted with the GMB-I-domain at pH 8.5 
and 6.6 to make PLP-I-domain-1 and PLP-I-domain-2, respectively. In this case, the 
peptide conjugation is via nucleophilic attack of the maleimide groups on the GMB-I-
domain by the thiol group of the Cys residue on the peptide (Step 2, Fig. 1). Both crude 
products were purified by SEC; the desired PLP-I-domain-1 or -2 could be easily 
separated from PLP-Cys-OH or PLP-Cys-NH2 (Fig. 3A). The pure fractions of each PLP-
I-domain were pooled and concentrated. The crude and purified products were analyzed 
by SDS-PAGE gel against the parent I-domain (Fig. 3B). As expected, the parent I-
domain shows one single band with low molecular weight than the conjugates (lane 2, 
Fig. 3B). The gel of the crude product illustrates the presence of PLP-I-domain-1 or -2 
along with lower MW bands corresponding to PLP-Cys-OH or PLP-Cys-NH2, 
respectively (lanes 3 and 5, Fig 3B). The gel of purified PLP-I-domain-1 or -2 shows 
multiple bands on the gel with higher molecular weight than the parent I-domain and 
without the starting PLP-Cys-OH or PLP-Cys-NH2 (lanes 4 and 6, Fig. 3). The multiple 
bands on PLP-I-domain-1 and -2 were due to various levels of peptide conjugates. Using 
the gel visually, it is difficult to differentiate between PLP-I-domain-1 and -2. 
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Unreacted 
PLP-Cys
PLP-I-domain-1
Figure 3A. The SEC chromatogram of PLP-I-domain-1, which is separated from the 
PLP-Cys peptide. 
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PLP-I-domain before and after purification
1        2         3        4        5        6
20 kDa
Figure 3B. SDS-PAGE analysis of different proteins after staining with 
Coomassie blue: molecular weight marker (lane1), the parent I-domain protein 
(lane 2), the reaction mixture at pH 8.5 to make PLP-I-domain-1 (lane 3), the 
purified PLP-I-domain-1 (lane 4), the reaction mixture at pH 6.6 to make PLP-
I-domain-2 (lane 5), and the purified PLP-I-domain-2 (lane 6). 
 
 
 
 
184
The deconvoluted LC-MS data indicated that 0–5 PLP peptides were attached to the 
PLP-I-domain-1 or -2 with an average of 2.5 PLP peptides per I-domain (Fig. 3C). Each 
subpopulation of peaks in the spectra of PLP-I-domain-1 or -2 has various MW peaks due 
to the presence of different numbers of GMB groups, but the same number of PLP-Cys 
peptide attached to the I-domain. The complexity in each of the subpopulations arises 
from the hydrolysis products of maleimide Figure 4.13  The CD spectrum of each 
conjugate was similar to that of the parent I-domain protein (Fig. 3D), indicating that 
conjugation of PLP-Cys peptide to the I-domain preserves the native secondary structure 
of the protein. 
 
4.3.3 Prophylactic suppression of EAE by PLP-I-domain-1 and -2: 
The in vivo efficacies of PLP-I-domain-1 and -2 to suppress EAE were determined in 
SJL/J mice (Fig. 5). After PLP/CFA immunization of the mice on day 0, they were 
treated via i.v. injections with PLP-I-domain-1 or -2, negative controls (PBS, I-domain, 
GMB-I-domain), or positive controls (Ac-PLP-cIBR7-NH2 and Ac-PLP-LABL-NH2). 
The mice treated with PBS, I-domain, and GMB-I-domain showed disease signs of EAE 
from days 8 to 17 after immunization with clinical scores as high as 4 (Fig. 5A). Similar 
trends were observed in loss of body weight of animals treated with these negative 
controls (Fig. 5B). At day14, 95% or more of the mice in these three groups had EAE 
(Fig. 5C). Both positive controls were significantly more effective in suppressing EAE 
than was to PBS (p < 0.001 for clinical scores and body weights). Ac-PLP-cIBR7-NH2 
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Figure 3C. Deconvoluted mass spectra of LC ESI-MS analysis of the PLP-I-domain-1 
preparation (top) and PLP-I-domain-2 (bottom). 
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had a better efficacy than Ac-PLP-LABL-NH2 with the onset of the disease delayed by 7 
and 4 days, respectively (Fig. 5A). 
Mice treated with PLP-I-domain-1 have significantly lower EAE clinical scores (Fig. 
5A) and minimal or no loss of body weight (Fig. 5B) compared to mice treated with PBS 
(p < 0.001), I-domain, and GMB-I-domain. All the mice receiving PLP-I-domain-1 
remained 100% disease-free until the end of the study (Fig. 5C). EAE clinical scores 
throughout the course of the study did not show any significant difference (p > 0.05) 
between PLP-I-domain-1-treated and Ac-PLP-cIBR7-NH2-treated mice (Fig. 5A). The 
clinical scores were significantly lower (p < 0.05) in PLP-I-domain-1-treated mice 
compared to Ac-PLP-LABL-NH2-treated mice, in spite of the higher dose of Ac-PLP-
LABL-NH2. 
It is interesting to find that PLP-I-domain-2 significantly delayed the onset of EAE 
compared to the PBS-treated group by about 2 days (p < 0.001; from day 10 to 16), but 
was not as potent as PLP-I-domain-1 (Fig. 5A and C). Eventually, there was no 
significant difference in the disease severity of mice treated with PLP-I-domain-2 and 
PBS beyond day 16 until the end of the study. Weight loss throughout the course of the 
study did not show any significant difference (p > 0.05) between PLP-I-domain-2-treated 
mice and those receiving PBS (Fig. 5B). The EAE clinical scores of mice treated with 
PLP-I-domain-2 were significantly higher (p < 0.001) than those treated with Ac-PLP-
cIBR7-NH2 and Ac-PLP-LABL-NH2. A similar trend was observed in the loss of body 
weight. Finally, the difference in the in vivo efficacy of PLP-I-domain-1 and -2 may be to 
the difference in the chemical structures of the two molecules. 
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Figure 5A. In vivo activity of PLP-I-domain-1 and -2 in mouse EAE model. Disease 
progression was evaluated using clinical disease scores. After immunization with 
PLP peptide in CFA, the mice received i.v. injections of 26 nmol of the conjugate 
PLP-I-domain-1, PLP-I-domain-2, GMB-I-domain, or I-domain on days 4 and 7. 
For the Ac-PLP-cIBR7-NH2 treatment group, the mice received i.v. injections of 52 
nmol of the Ac-PLP-cIBR7-NH2 peptide on days 4 and 7. For the Ac-PLP-LABL-
NH2 treatment group, the mice received i.v. injections of 100 nmol of the Ac-PLP-
LABL-NH2 peptide on days 4, 7, and 10. The results are expressed as the mean 
S.E. (n  6). There are significant differences between PLP-I-domain-1 vs. GMB-I-
domain, I-domain, or PBS-treated group in clinical disease score (p < 0.001, through 
days 9–20). There are significant differences between PLP-I-domain-2 vs. PBS-
treated group in clinical disease score (p < 0.001, through days 9–20). There are 
significant differences between PLP-I-domain-2 vs. GMB-I-domain or I-domain 
treated group in clinical disease score (p < 0.05, through days 9-20).
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Figure 5B. In vivo activity of PLP-I-domain-1 and -2 in mouse EAE model. 
Disease progression was evaluated using change in body weight. After 
immunization with PLP peptide in CFA, the mice received i.v. injections of 26 
nmol of the conjugate PLP-I-domain-1, PLP-I-domain-2, GMB-I-domain, or I-
domain on days 4 and 7. For the Ac-PLP-cIBR7-NH2 treatment group, the mice 
received i.v. injections of 52 nmol of the Ac-PLP-cIBR7-NH2 peptide on days 4 
and 7. For the Ac-PLP-LABL-NH2 treatment group, the mice received i.v. 
injections of 100 nmol of the Ac-PLP-LABL-NH2 peptide on days 4, 7, and 10. 
The results are expressed as the mean  S.E. (n  6). There are significant 
differences between PLP-I-domain-1 vs. GMB-I-domain, I-domain, or PBS-treated 
group in body weight (p < 0.001, through days 9–20). There are significant 
differences between PLP-I-domain-2 vs. GMB-I-domain or I-domain treated group 
in body weight (p < 0.001, through days 9–20).
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Figure 5C. In vivo activity of PLP-I-domain-1 and -2 in mouse EAE model. 
Disease progression was evaluated using incidence of disease. After 
immunization with PLP peptide in CFA, the mice received i.v. injections of 26 
nmol of the conjugate PLP-I-domain-1, PLP-I-domain-2, GMB-I-domain, or I-
domain on days 4 and 7. For the Ac-PLP-cIBR7-NH2 treatment group, the mice 
received i.v. injections of 52 nmol of the Ac-PLP-cIBR7-NH2 peptide on days 4 
and 7. For the Ac-PLP-LABL-NH2 treatment group, the mice received i.v. 
injections of 100 nmol of the Ac-PLP-LABL-NH2 peptide on days 4, 7, and 10. 
The results are expressed as the mean  S.E. (n  6). There are significant 
differences between PLP-I-domain-1 vs. GMB-I-domain, I-domain, or PBS-
treated group in disease incidence (p < 0.001, through days 9-20). There are 
significant differences between PLP-I-domain-2 vs. PBS-treated group in disease 
incidence (p < 0.001, through days 9–20). 
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4.3.4 Structural analysis of PLP-I-domain-1 and -2: 
To investigate the structural differences between PLP-I-domain-1 and -2, peptide 
mapping using tryptic digestion and mass spectrometry was used to determine the 
location of PLP peptides on the I-domain protein. The assumptions are that the modified 
lysine residues on the I-domain cannot be cleaved by trypsin, and the cleavaged product 
of the lysine residue that is attached to the PLP peptide can be used to identify the 
modified lysine residue on the I-domain. The modified peptide fragments were identified 
using LC-MS/MS. The PLP peptide contains a Lys residue (Lys12), which also could be 
hydrolyzed by trypsin to produce a dipeptide, Phe-Cys-OH or Phe-Cys-NH2, which is 
attached to maleimidobutyryloxy. These attached dipeptides have molecular weights of 
433.1307 Da for Phe-Cys-OH and 432.1467 Da for Phe-Cys-NH2. In addition, we 
observed Phe-Cys-OH and Phe-Cys-NH2 conjugated to the peptide fragment via the 
hydrolysis product of maleimide which has 18.0106 Da molecular weight added. The 
comparison of LC-MS/MS data from tryptic-digest fragments of the conjugates is 
summarized in Table 2. The LC-MS/MS sequence coverage for PLP-I-domain-1 and -2 
was 99% and 94%, respectively. A total of 15 modified tryptic peptides were identified 
from PLP-I-domain-1 and 10 peptides from PLP-I-domain-2. All of the conjugation sites 
were partially modified, and the number of unmodified peptides dominated the search 
profile. These modified peptides were unique and were found in the mapping profiles of 
the conjugates but not in the parent I-domain profile. The experimental and the calculated 
mass values of the modified peptides were very close, with the average deviation being 
less than 0.1 Da. There was only one modified peptide missing in the PLP-I-domain-1  
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Table 2. Modification sites in PLP-I-domain-1 and -2 detected in peptides from trypsin 
digestion 
Modified 
peptide Sequence 
PLP-I-
domain-1 
PLP-I-
domain-2 
Modified 
sites 
T1 1MGNVDLVFLFDGSMSLQPDEFQ23K Yes Yes M1 
T2-3 24ILDFMKDVM33K Yes No K29 
T4-5 34KLSNTSYQFAAVQFSTSY52K Yes Yes K34 
T6-7 53TEFDFSDYVK63R Yes Yes K62 
T8-9 64KDPDALL71K Yes No K64 
T9-10 65DPDALLKHV74K Yes Yes K71 
T12-13 96EELGARPDATKVLIIITDGEATDSGNI
DAA126K Yes No K106 
T13-14 107VLIIITDGEATDSGNIDAAKDII130R Yes Yes K126 
T15-16 131YIIGIGKHFQT142K Yes Yes K137 
T16-17 138HFQTKESQETLH150K Yes No K142 
T18 151FASKPASEFV161K Yes No K154 
T18-19 151FASKPASEFVKILDTFE168K Yes Yes K161 
T19-20 162ILDTFEKL170K Yes Yes K168 
T20-21 169LKDLFTELQ178K Yes Yes K170 
T21-22 171DLFTELQK179K Yes No K178 
T20-23 169LKDLFTELQKKI181Y No Yes K179 
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that was identified in PLP-I-domain-2. In contrast, there were 6 modified peptides 
missing in PLP-I-domain-2 that were present in PLP-I-domain-1 (Table 2); for example, 
Lys154 (K154) was modified in PLP-I-domain-1 but not in PLP-I-domain-2.  
 
4.4 DISCUSSION 
Patients with autoimmune diseases such as multiple sclerosis (MS), rheumatoid 
arthritis (RA), and psoriasis are currently being treated with protein-derived drugs such as 
monoclonal antibodies and peptide polymers, which modulate the immune system. 
Current treatments of MS patients include Copaxone® and Tysabri® as well as anti-
inflammatory agents (e.g., corticosteroids, beta-interferon-1a, mitoxantrone).  Some of 
the drugs for MS have been shown to have different side effects in patients, including the 
suppression of the general immune response, which can lead to undesirable pathogenic 
infections. Tysabri® is a monoclonal antibody that binds to the α4-subunit of α4β1 and 
α4β7 integrins to block leukocyte adhesion and infiltration into CNS. Although this drug 
is effective, patients treated with Tysabri® were found to develop progressive multifocal 
leuko-encephalopathy (PML), a life-threatening complication in patients.14 PML was also 
observed in patients treated with Raptiva (Efalizumab, CD11a mAb) for psoriasis; thus, 
this drug was withdrawn from the market.15-16 Because Tysabri® and Raptiva bind to 
integrins, these antibodies presumably also suppress Signal-2 for T-cell activation in 
addition to blocking the cell adhesion. Blocking Signal-2 of the immunological synapse 
formation suppresses the general activation of T cells that can respond to pathogens such 
as JC virus that causes PML. Therefore, there is a need to discover a new way to suppress 
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T-cell activation in an antigen-specific manner without suppressing the general immune 
responses. 
To address the issue of antigen specific disease suppression while preserving the 
immune system’s ability to fight to foreign pathogens, our group developed BPI 
molecules (GAD-BPI, PLP-BPI, and CII-BPI),3-7 which were derived from antigenic 
peptides discovered by others.17-22 In parallel with the design of BPI molecules, the PLP-
I-domain molecules were developed by attaching several antigenic peptides to one 
molecule of I-domain. Thus, the advantage of making PLP-I-domain is that the I-domain 
can be used to carry multiple copies of the antigenic peptides to improve the potency of 
the conjugate. In addition, the I-domain can also be utilized to carry multiple and 
different antigenic peptides to modulate different subpopulations of antigen-specific T 
cells. Similar to BPI, PLP-I-domain conjugates are hypothesized to inhibit the 
immunological synapse formation during the process of T-cell activation by simultaneous 
binding of the PLP peptide and I-domain to MHC-II and ICAM-1, respectively, on APC. 
This simultaneous binding forms a bridge between the two receptors and eventually 
prevents the translocation and reorganization of Signal-1 and Signal-2.   
In the present study, it was found that just two i.v. injections (26 nmol/injection) of 
PLP-I-domain-1 inhibited the onset and progress of EAE more efficiently than PBS alone 
or three injections (100 nmol/injection) of Ac-PLP-LABL-NH2. Also, there was no 
significant difference between two injections of PLP-I-domain-1 and Ac-PLP-cIBR7-
NH2. The improved efficacy of PLP-I-domain-1 could be due to the higher binding 
efficiency of I-domain to ICAM-1 than that of LABL peptide in Ac-PLP-LABL-NH2 or 
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it could be due to the delivery of multi-antigenic peptides. Thus, the mechanisms of the 
way that PLP-I-domain-1 regulates the autoimmunity are currently being investigated. 
Another conjugate, PLP-I-domain-2, was synthesized using PLP-Cys-NH2 peptide, 
which has an amide group on the C-terminus. The optimal conjugation of PLP-Cys-NH2 
to I-domain was at pH 6.6. It is interesting to find that two i.v. injections 
(26nmol/injection) of PLP-I-domain-2 produce some delay in the onset and severity of 
the disease compared to PBS, but not to the same extent as PLP-I-domain-1. PLP-I-
domain-2 is also less potent than Ac-PLP-LABL-NH2 and Ac-PLP-cIBR7-NH2. The 
analyses of both PLP-I-domain-1 and -2 indicate that both molecules contain an average 
of 2.5 peptide molecules per I-domain molecule. The SDS-PAGE and CD analyses could 
not differentiate between the two molecules. Thus, it is possible that the difference in in 
vivo activity of these two molecules could be due to the locations of the conjugated 
peptides and/or the nature of the C-terminal form of PLP peptide—whether it is capped 
with amide or in free carboxylic acid form. 
To determine the difference in the conjugation sites, both conjugates and the parent I-
domain were subjected to tryptic digestion followed by LC-MS/MS analysis. PLP-I-
domain-1 has a total of 15 lysine sites that are modified by PLP-Cys-OH peptide 
compared to PLP-I-domain-2 with 10 lysine sites that are modified by the PLP-Cys-NH2. 
The difference in the pH of reaction (8.5 and 6.6) could contribute to the location of 
conjugation on the GMB-I-domain protein (Step 2). It has been shown that reactivity of 
thiol group in attacking the maleimide group is accelerated by increasing the pH.13 This is 
consistent with the higher number of conjugation sites on PLP-I-domain-1 compared to 
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PLP-I-domain-2. At this time, it has not yet been determined whether the nature of the C-
terminus of the PLP peptide has an effect on the conjugation sites. It is most likely that 
the nature of the peptide C-terminus does not contribute greatly to the number of sites of 
conjugation.  
There are sites of peptide conjugation present in PLP-I-domain-1 that are not found in 
PLP-I-domain-2; these sites include K29, K64, K106, K142, K154, and K178 (Fig. 6). 
The observable difference in the activity of PLP-I-domain-1 and PLP-I-domain-2 
suggests that conjugation of PLP peptides on K29, K64, K106, K142, K154, and K178 
contributes to the activity of PLP-I-domain-1, and the absence of peptides on these sites 
in PLP-I-domain-2 makes it less potent to suppress EAE. The difference in the C-
terminus of PLP peptide may not contribute to the lower activity of PLP-I-domain-2; our 
previous studies showed that amidation of the C-terminus BPI molecules containing PLP 
peptide enhanced the in vivo activity of BPI molecules. The locations of the modified 
K29, K64, K106, K142, K154, and K178 are indicated in the structure of I-domain 
(yellow ribbons, Fig. 7). If the activity of PLP-I-domain-1 is due to its simultaneous 
binding to ICAM-1 and MHC-II on the surface of APC, the most active conjugate should 
accommodate binding to these two receptors. It is known that the I-domain binds to 
ICAM-1 via its MIDAS region (magenta, Fig. 7). From the model derived from the X-ray 
structure, it can be predicted that conjugation of PLP peptide at K142 and K178 would be 
the most probable sites to accommodate simultaneous binding of PLP-I-domain-1 to 
MHC-II and ICAM-1. In the future, the most important site(s) for peptide conjugation 
will be determined using a single mutation of each Lys residue (i.e., K29, K64, K106, 
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Figure 7. The X-ray structure of I-domain (PDB code 1ZON). The residues in 
blue are the lysine modification sites found in PLP-I-domain-1 but not in PLP-I-
domain-2 and the residues in pink are located in the MIDAS region. The N- and 
C-termini are labeled as N- and C-, respectively. The protein images were created 
using Accelrys DS Visualizer 1.7. (A) Side view. (B) Top view.
6
MIDASA
LYS142
C-
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K142, K154, or K178) to a Cys residue followed by conjugation of PLP peptide. In this 
case, the peptide will be derivatized with a maleimide group. To illustrate, Lys142 can 
mutated with Cys142 to give Cys142-I-domain. Then, Cys142-I-domain will be 
conjugated with PLP peptide to give PLP-Cys142-I-domain, and the in vivo activity of 
this new conjugate will be determined in the EAE mouse model.  Using this method, we 
can pinpoint the conjugation site(s) that is important for the activity of the PLP-I-domain 
molecule. It is possible that multiple sites of peptide conjugation are necessary; in such a 
case, multiple Cys mutations can be carried out on a single I-domain protein.  
 
 
4.5 CONCLUSIONS 
We have shown the proof-of-concept that PLP-I-domain-1 has excellent efficacy in 
inhibiting the progress of EAE in the mouse model. This study also indicates that the 
location(s) of peptide conjugation on the I-domain has an impact on the in vivo activity. 
In the future, we will study the mechanism of action of PLP-I-domain-1 in regulating the 
immune response in EAE. If the PLP-I-domain has a mechanism of action similar to that 
of BPI molecules, we expect that treatment of EAE mouse with PLP-I-domain-1 will 
increase the production of IL-10, IL-4, and TGF-β cytokines, which possibly tips the 
balance from TH1 and TH17 to Treg and TH2 differentiations. Another consideration is that 
the presence of antigen spreading in autoimmune diseases such as MS can be solved with 
multiple sites of conjugation with different peptides on I-domain protein. For example, 
antigenic peptides PLP, myelin basic protein (MBP), and myelin oligodendrocyte 
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glycoprotein (MOG) can be simultaneously conjugated to I-domain to cover different 
subpopulations of T cells. In such conditions, conjugation of each I-domain molecule 
with all the three immunodominant epitopes may offer a unique approach for the 
treatment of MS. 
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Summary, Conclusions, and Future Directions 
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SUMMARY AND CONCLUSIONS 
The objective of the current work was to utilize the I-domain protein to deliver 
antigenic peptides (i.e., PLP peptide) to control EAE in an antigen-specific manner in the 
mouse model for MS. I-domain is a well characterized protein; it contains a major 
ICAM-1 binding site and can block T-cell binding to immobilized recombinant ICAM-1-
Fc.1-3 The I-domain protein has a unique divalent cation coordination site called metal 
ion-dependent adhesion site (MIDAS) that interacts with the D1 domain of ICAM-1.1, 4-6 
Up to this point, the binding and internalization properties of the soluble I-domain to 
ICAM-1 on the cell surface have not been studied. Furthermore, its utility to target drugs 
to lymphocytes has not been explored. 
In this work, we conjugated a fluorescein molecule (FITC) to I-domain protein for 
studying its ICAM-1-binding and uptake properties on B-lymphocytes (Raji cells). The 
data were used to predict I-domain applicability for targeting drug molecules to cells with 
upregulated ICAM-1 expression. The FITC conjugation was to the -amino group of the 
lysine residues and the N-terminus of the I-domain to generate FITC-I-domain. The 
binding of FITC-I-domain to ICAM-1 on Raji cells was blocked by anti-I-domain mAb, 
suggesting that the antibody binds to the ICAM-1 binding site of the I-domain. In 
contrast, incubation of an anti-ICAM-1 mAb on the cells enhanced the binding of FITC-
I-domain to ICAM-1; this result suggests that anti-ICAM-1 mAb has an allosteric effect 
on I-domain binding. A detailed structural analysis of FITC-I-domain using tryptic 
digestion followed by LC MS analysis showed that the FITC modifications were found at 
the lysine residues away from the MIDAS region. These findings indicate that FITC 
 
 
 
208
derivatization of the I-domain does not influence the binding properties of FITC-I-
domain to ICAM-1 on Raji cells.  
To determine the cellular uptake of FITC-I-domain, confocal microscopy studies 
followed by cell image analyses were performed using Raji cells incubated with FITC-I-
domain at either 4 or 37 °C with increasing incubation time. This study showed that the 
average integrated fluorescence intensity values associated with the cytoplasm were 
increasing with the incubation time at 37 °C but not at 4 °C. These results indicate that 
FITC-I-domain internalizes in Raji cells via an energy-dependent process.  
The applicability of the I-domain conjugate to deliver drug molecules or peptides to 
antigen-presenting cells (APC) was evaluated in the EAE animal model, a model for 
multiple sclerosis. In this case, antigenic peptides from proteolipid protein (PLP) were 
conjugated with the I-domain to produce PLP-I-domain-1 and -2. PLP-I-domain-1 and -2 
were prepared by conjugating PLP-Cys-OH and PLP-Cys-NH2 at pH 8.5 and 6.6, 
respectively, to the I-domain. Both the conjugates had similar characteristics as 
determined by SDS-PAGE, mass spectrometry, and CD analysis. In mice treated with 
two i.v. injections (26 nmol on days 4 and 7) of PLP-I-domain-1, the onset and 
progression of EAE were inhibited more significantly than in PBS-treated mice. Mice 
treated with PLP-I-domain-2 showed some delay in the onset and severity of EAE 
compared to PBS, but PLP-I-domain-2 has a lower efficacy than PLP-I-domain-1. PLP-I-
domain-1 but not PLP-I-domain-2 was found to have better potency than three i.v. 
injections of 100 nmol of Ac-PLP-LABL-NH2 administered on days 4, 7, and 10. PLP-I-
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domain-1 activity was similar to that of Ac-PLP-cIBR1-NH2 (i.e., 52 nmol i.v. injections 
on days 4 and 7).  
To investigate the structural differences between the two conjugates (PLP-I-domain-1 
and -2), they were subjected to tryptic digestion and LC-MS/MS analysis. The results 
show that PLP-I-domain-1 has a total of 15 modification sites in contrast to PLP-I-
domain-2, which has 10 modification sites. The difference in the number of modification 
sites could be due to differences in their reaction conditions (i.e., pH 8.5 and 6.6) and, to 
a lesser extent, to the difference in the C-termini of the PLP peptides. The additional 
conjugation sites on PLP-I-domain-1 compared to PLP-I-domain-2 may contribute to the 
excellent in vivo activity of PLP-I-domain-1.  
In conclusion, the current work is the first study to show that I-domain can bind and 
enter into the cytoplasmic compartment of immune cells; therefore, it can be utilized to 
deliver drugs to ICAM-1-expressing target cells. Most importantly, PLP-I-domain-1 can 
suppress the progression of EAE in the mouse model. The fact that PLP-I-domain-1 has 
superior activity compared to PLP-I-domain-2 suggests that the location(s) of peptide 
conjugation on the I-domain protein have a significant impact on the conjugate efficacy.   
 
FUTURE DIRECTIONS 
Exploring the possible mechanisms of action of PLP-I-domain conjugate: 
In vivo studies in EAE mice indicate that treatment of mice with Ac-PLP-LABL-NH2 
significantly increases the TGF-, IL-10, IL-4 production and decreases the IFN- 
production compared to treatment with PBS.7 We predict that treatment with PLP-I-
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domain suppresses the IFN- producing TH1 cells and induces the differentiation of TGF-
- and IL-10-producing Treg cells and IL-4 producing TH2 cells. We propose that there is 
a shift in the balance from immunogenic to immnuotolerant response. Because of the 
elevated levels of IL-17 in patients with MS, it would be interesting to determine the 
plasma levels of IL-17 and the presence of TH17 cells in the EAE animal model upon 
treatment with PLP-I-domain-1. In the future, we will determine the plasma cytokine 
levels (IL-10, TGF-, IL-4, IFN-, and IL-17) along with the presence of different T-cell 
subpopulations (TH1 and TH17 vs. TH2 and Treg) in mice treated with PLP-I-domain-1 and 
PBS. The results from these proposed studies will shed light on the potential 
mechanism(s) of action of PLP-I-domain-1. 
 
Conjugation of antigenic peptide at a specific site on I-domain: 
It is important to determine the crucial modification site(s) on the I-domain protein 
that contributes to the activity of PLP-I-domain-1. Our hypothesis is that the activity of 
PLP-I-domain may be due to its simultaneous binding of PLP-I-domain-1 to MHC-II and 
ICAM-1 on the surface of APC. Chapter 4 provides insight into probable site(s) where 
PLP conjugation may facilitate such simultaneous binding. For example, attachment of 
PLP peptide on Lys142 was found on PLP-I-domain-1 but not on PLP-I-domain-2. It 
should be noted that Lys14 is adjacent to the MIDAS region on I-domain. Thus, the 
conjugation of PLP peptide at Lys142 may accommodate binding of PLP-I-domain 
conjugate to MHC-II and ICAM-1 on APC to inhibit the immunological synapse 
formation. To test this hypothesis, we will selectively mutate Lys142 to Cys142 to give 
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Cys142-I-domain. Then, the thiol group of Cys142 in Cys142-I-domain will be 
conjugated to PLP peptide containing a maleimido group to produce PLP-Cys142-I-
domain conjugate (Fig. 1). It is expected that the PLP-Cys142-I-domain will be a 
homogeneous product because the original I-domain protein has no cysteine residue. The 
in vivo efficacy of PLP-Cys142-I-domain will be compared to that of PLP-I-domain-1 
and PBS in the mouse EAE model. Other single mutations and conjugations will be 
evaluated in vivo. These studies will locate the important peptide conjugation site(s) on 
the I-domain protein that contribute to the in vivo activity of the conjugate. Furthermore, 
multiple mutations can be carried out in I-domain for delivering multiple antigenic 
peptides to APC to overcome the potential antigen spreading in multiple sclerosis (see 
below). 
 
Application of antigenic peptide-I-domain conjugates for suppression of other 
autoimmune diseases: 
The general applicability of antigenic peptide-I-domain to treat different autoimmune 
diseases such as rheumatoid arthritis (RA) and type 1 diabetes (T1D) may be tested by 
conjugating the I-domain to an antigenic peptide specific for that particular disease. For 
example, the antigenic peptide (i.e., PLP-) in PLP-I-domain can be replaced with 
antigenic peptide from collagen-II (CII256–270) antigen and with glutamic acid 
decarboxylase (GAD208–217) antigen to prepare CII-I-domain and GAD-I-domain, 
respectively. The efficacies of CII-I-domain and GAD-I-domain can be evaluated 
respectively in the collagen-induced arthritis (CIA) mouse (a model for RA) and non-
 
 
 
212
SH
Cys142-I-domain
HSLGKWLGHPDKF
-maleimidobutyryloxy-PLP139-151
Id N
H
N
O
O
O
pH 6.5-7.5
S
HSLGKWLGHPDKF
Id
N
H
N
O
O O
PLP-Cys142-I-domain
Figure 1. Schematic representation of a single-step modification of Cys142-
I-domain mutant with -maleimidobutyryloxy-PLP139-151 to produce PLP-
Cys142-I-domain conjugate.
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obese diabetes (NOD) mouse (a model for T1D). It will be interesting to evaluate 
whether there is a common general mechanism of action of antigen-I-domain conjugates 
in different autoimmune diseases.  
 
Targeting multivalent antigenic peptides using I-domain protein: 
One of the main reasons why autoimmune diseases are considered to be complex is 
because of the possibility of antigen or epitope spreading. In such cases, immune cells 
change their response from targeting the primary epitope to targeting many different 
epitopes on an autoantigen.8-10 Epitope spreading may complicate the application of 
specific therapies designed to interfere with immune cells that recognize a single antigen. 
One possible solution to this scenario is to develop a novel therapy that can cover 
different subpopulations of T cells that recognize different self antigens. In this case, the 
I-domain protein is an excellent choice for conjugating multiple antigenic peptides on the 
lysine residues. For example, antigenic peptides from PLP, myelin basic protein (MBP), 
and myelin oligodendrocyte glycoprotein (MOG) are simultaneously conjugated to a 
single I-domain molecule (Fig. 2) to give a mixture of PLP/MBP/MOG-I-domain that can 
respond to suppress the proliferation of subpopulations of inflammatory T cells, which 
are sensitive to these various antigens in the EAE mouse model. 
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Figure 2. Schematic representation of modification and conjugation 
reactions in the preparation of a multivalent antigenic peptide-I-domain 
conjugate. Step 1: Modification of the I-domain protein with GMBS. 
Step 2: Conjugation of PLP, MBP, and MOG to GMB-I-domain.
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